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ABSTRACT 
 
Premature adrenarche (PA) is defined as adrenarcheal levels of adrenal androgens before the age of 8 yrs 
in girls and the age of 9 yrs in boys leading to androgenic signs ranging from pubarche to oily skin and 
adult type body odor. PA has been connected with adverse metabolic features and increased risk for 
ovarian hyperandrogenism. The pathogenesis of PA is considered polygenic. However, underlying genetic 
factors remain largely unknown. 
   We aimed to determine the role of genetic variation of PA candidate genes in a case-control cohort of 
prepubertal PA children (63 girls and 10 boys) and their age- and gender-matched controls (79 girls and 18 
boys). The following candidate genes with previously described polymorphisms were selected based on 
the current knowledge of PA: ACTH receptor (MC2R), androgen receptor (AR), low density lipoprotein 
receptor-related protein 5 (LRP5), transcription factor 7-like 2 (TCF7L2), and fat mass and obesity 
associated gene (FTO). We compared genotype distributions between the PA and control groups, and used 
single marker association analyses to relate genetic variants with clinical phenotype. 
   The minor variant of the single nucleotide polymorphism (SNP) MC2R -2 T>C was more frequent in 
subjects with premature pubarche than in children with milder signs of PA and controls. The minor variant 
was associated with a higher ratio of ACTH to cortisol in the control group, in agreement with previous 
studies that have shown decreased ACTH sensitivity due to the polymorphism. In children with PA, the 
minor variant associated with higher androstenedione level and ratio of androstenedione to cortisol, 
suggesting shifting of steroidogenesis from corticosteroids to androgens. The length of CAGn at X-
chromosomal AR correlates inversely with the activity of AR. Children with PA had a shorter CAGn repeat 
than the controls, and the difference became even stronger when we took the X-chromosome inactivation 
into account. The lean PA children with a BMI below the median of the group had a shorter CAGn than 
the PA children with higher BMI or the controls with the same BMI. More active AR may have a 
significant role in the pathogenesis of PA in these lean children. Minor variants at SNPs A1330V and 
N740N of LRP5 were associated with higher dehydroepiandrosterone sulfate and cholesterol levels in 
control children, but no association between genetic variants at LRP5 and clinical parameters was 
observed in the children with PA. The minor variant at rs7903146 of TCF7L2 was more frequent in lean 
PA children. The minor variant at rs9939609 of FTO was not more frequent in children with PA, 
suggesting that this genetic variant in FTO has no major role in the increased BMI of PA children. The 
power of the study was limited, and the results need to be confirmed in different populations. However, 
the value of the study lies in the use of unbiased controls and in the precise phenotyping of all the children 
from a homogenous population. 
   In conclusion, MC2R -2 T>C may have a role in the pathogenesis of premature pubarche. Lean PA 
children show a different genotype, with a shorter CAGn repeat, indicating a more active AR, and 
increased frequency of the minor variant at rs7903146 of TCF7L2 in comparison to PA children with 
higher BMI. 
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Genetic Variation; Genotype; Phenotype; Polymorphism, Genetic; Receptors, Androgen; Receptors, Corticotropin; 
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A   Adenine 
ACTH   Adrenocorticotropic hormone 
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BMI   Body mass index 
BP   Blood pressure 
C   Cytosine 
CAGn   Cytosine-adenine-guanine repeat length 
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DAX-1  Dosage-sensitive sex reversal, adrenal hypoplasia congenital, critical region 
on the X-chromosome, gene-1 
DHEA   Dehydroepiandrosterone 
DHEAS  Dehydroepiandrosterone sulfate 
DHT   Dihydrotestosterone  
DNA   Deoxyribonucleic acid 
FOH  Functional ovarian hyperandrogenism  
FTO   Fat mass and obesity-associated gene 
G   Guanine 
GAD2   Glutamate decarboxylase 2 
GnRH   Gonadotropin-releasing hormone 
GWA   Genome wide association 
HDL   High-density lipoprotein 
HSD17B5  Hydroxysteroid 17β-dehydrogenase 5 
HOMA-IR Homeostasis model assessment for insulin resistance 
IGF   Insulin-like growth factor 
IGFBP   Insulin-like growth factor binding protein 
IGF-1R   Type 1 IGF receptor  
ISIcomp  Insulin sensitivity index 
LDL   Low-density lipoprotein 
LD   Linkage disequilibrium 
LRP5   Low density lipoprotein receptor-related protein 5 
MAF   Minor allele frequency 
MC2R   Melanocortin-2 receptor 
mRNA   Messenger ribonucleic acid 
mwCAGn Methylation weighted biallelic means of CAGn 
OGTT   Oral glucose tolerance test 
PA   Premature adrenarche 
PAI-1   Plasminogen activator inhibitor-1  
PCOS   Polycystic ovary syndrome 
PP   Premature pubarche 
 
  
SDS   Standard deviation score 
SERKAL Sex reversal, female, with dysgenesis of kidneys, adrenals and lungs 
SF-1   Steroidogenic factor-1 
SHBG   Sex hormone-binding globulin 
SNP   Single nucleotide polymorphism 
SORBS1  Sorbin and SH3 domain containing 1 gene  
SULT2A1  DHEA sulfotransferase 
T   Thymine 
TCF7L2  Transcription factor 7-like 2 
T2DM  Type 2 diabetes mellitus  
UGT2B   Uridine diphospho-glucorunosyltransferase 2B 
Vmax   Maximum velocity of the enzyme catalytic activity 
VNTR   Variable number of tandem repeats  
Δ4-A   Androstenedione 
17OHP   17-hydroxyprogesterone 
3βHSD   3β-hydroxysteroid dehydrogenase 
3’ UTR  3’ untranslated region 
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1 INTRODUCTION 
 
Adrenarche is unique to humans and higher primates in whom the production of adrenal 
androgens follows an age- and gender-dependent pattern (Parker 1999). During fetal 
development, the fetal cortex of the adrenal gland secretes large amounts of androgens which 
act as precursors for the estrogen production in the placenta (Siiteri and MacDonald 1966). 
After birth, the fetal cortex disappears and the levels of adrenal androgens decrease. Adrenal 
androgens stay low until adrenarche, the rise in adrenal androgen levels after the age of 6 yrs, 
preceding the activation of central puberty (de Peretti and Forest 1976, Mesiano and Jaffe 
1997). At puberty, the adrenal androgen levels rise to a higher level in men than in women, and 
dehydroepiandrosterone sulfate (DHEAS) has the highest circulating plasma level of all steroid 
hormones in adults with a slow decline during aging (Rosenfield et al. 1982, Labrie et al. 1997, 
Nafziger et al. 1998). Adrenocorticotropic hormone (ACTH) stimulates adrenal androgen 
secretion, but no change in circulating ACTH levels is seen during adrenarche (Nieschlag et al. 
1973, Apter et al. 1979). It is not known which factors awaken the reticular zone of the adrenal 
cortex to secrete androgens at adrenarche. 
   Premature adrenarche (PA) is defined as the adrenarcheal levels of adrenal androgens 
(DHEAS above 1 µmol/l) in girls before the age of 8 yrs and in boys before the age of 9 yrs, 
resulting in androgenic signs ranging from growth of pubic hair (premature pubarche, PP) and 
axillary hair (Silverman et al. 1952, Thamdrup 1955) to oily hair and skin (Rosenfield et al. 
1982), adult-type sweating and body odor (Voutilainen et al. 1983, Kaplowitz et al. 1986, 
Likitmaskul et al. 1995). PA was long considered a benign variant of pubertal development 
until it was connected in the '90s with adverse metabolic features and a possible risk for ovarian 
hyperandrogenism (Rosenfield 1994, Dimartino-Nardi 1999, Ibáñez et al. 2000a). The 
pathogenesis of PA is considered polygenic, and possible associations have been investigated in 
genes participating in steroidogenesis (Witchel et al. 2001, Petry et al. 2005), androgen action 
(Ibáñez et al. 2003b, Vottero et al. 2006), and in the functions of insulin and insulin-like growth 
factors (IGF) (Ibáñez et al. 2002, Roldan et al. 2007). However, the pathogenesis of PA remains 
largely unknown.   
   Predispoding genetic factors for adrenarche remain to be identified in the human genome. The 
development of genetic analyses made it possible to construct the sequence of the whole human 
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genome, also revealing the millions of single nucleotide polymorphisms and other structural 
variants within the genome (International Human Genome Sequencing Consortium 2004). 
Genotype-phenotype associations have been studied, but the mechanisms between genetic 
variants and clinical phenotype are difficult to solve. By searching for associations between 
genetic variants and phenotype, we can gain insight into the mechanisms behind PA. This was 
the aim of the thesis. 
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2 REVIEW OF THE LITERATURE 
 
2.1 ADRENARCHE 
 
2.1.1 Physiology of adrenal androgen production 
 
The adrenal cortex secretes androgens androstenedione (Δ4-A), dehydroepiandrosterone 
(DHEA) and its sulfated form DHEAS in age- and gender-dependent pattern (Parker 1999). 
During the fourth week of gestation, coelomic epithelial cells and underlying mesonephric 
mesenchymal cells migrate to form the adrenogonadal primordium, of which the primitive 
adrenal and gonadal primordial cells separate by the eight week of gestation (Mesiano and Jaffe 
1997). The key regulators of adrenal development are the orphan nuclear receptors DAX-1 
(dosage-sensitive sex reversal, adrenal hypoplasia congenital, critical region on the X-
chromosome, gene-1) and steroidogenic factor-1 (SF-1). Mutations in these transcription factors 
have also been found in patients with adrenal hypoplasia (Muscatelli et al. 1994, Zanaria et al. 
1994, Achermann et al. 1999, Lin et al. 2006). During fetal development, the fetal cortex of the 
adrenal gland secretes huge amounts of adrenal androgens for the placental estrogen production 
(Siiteri and MacDonald 1966). Soon after birth, the fetal cortex regresses by apoptosis and 
adrenal androgen levels decrease, remaining low until the time of adrenarche, the reactivation 
of adrenal androgen production (de Peretti and Forest 1976, Mesiano and Jaffe 1997, Lashansky 
et al. 1991). Adrenarche occurs slightly earlier in girls than in boys (Sizonenko and Paunier 
1975, Ducharme et al. 1976), but DHEAS levels in boys exceed those in girls around the age of 
20 years (Rosenfield et al. 1982). DHEAS has the highest circulating plasma level of all steroid 
hormones in adults. With aging, DHEAS levels decline on average 2% per year from the 
highest levels in the twenties through the sixties (Labrie et al. 1997, Nafziger et al. 1998) 
   Adrenal androgens are considered weak androgens, which can be converted to stronger 
androgens and estrogens by target tissues, and their effects are mediated by nuclear hormone 
receptors. The visible signs of adrenarche include growth of pubic and axillary hair, oily hair, 
comedones, acne, and the development of adult type sweat secretion and body odor in children. 
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Adrenal androgens also participate in growth and bone maturation. As adrenal androgens are 
also neurosteroids (Goodyer et al. 2001), adrenarche may have a role in brain development 
(Suzuki et al. 2004). It has been proposed that adrenarche promotes changes in behavior and 
cognition preparing children for the challenges of puberty (Campbell 2006, Hochberg 2008). 
   Adrenarche results from the formation of continuous innermost layer of adrenal cortex called 
zona reticularis which secretes mainly DHEA and DHEAS (Dhom 1973, Reiter et al. 1977). 
The medullary capsule separating the cortex and medulla of the adrenal gland breaks down, and 
the focal development of zona reticularis starts at the age of 5 yrs. A continuous zone is usually 
present by the age of 8 yrs (Dhom 1973). The first appearance of zona reticularis cells is 
detected at the age of 3 yrs, and some studies have shown a gradual rise in adrenal androgen 
levels already from that age (Palmert et al. 2001, Remer et al. 2005). The outer layers of the 
adrenal cortex, the zona glomerulosa and fasciculata, secrete mineralocorticoids and 
glucocorticoids, respectively. The adrenal medulla secretes catecholamines. The zones of the 
adrenal cortex are formed by migration of undifferentiated cells from the gland periphery under 
the gland capsula toward the medulla. As the cells migrate, they differentiate to have zone 
specific steroidogenic capacities (Kim and Hammer 2007).  
   Like all steroid hormones, also adrenal androgens are produced from cholesterol (Figure 1). 
Cholesterol enters the mitochondria with the assistance of the steroidogenic acute regulatory 
protein (StAR). Within the mitochondria, cholesterol is converted to pregnenolone by the 
cholesterol side chain cleavage enzyme (P450scc). Pregnenolone undergoes 17α-hydroxylation 
by microsomal P450c17, and 17-hydroxypregnenolone is further converted to DHEA by the 
17,20-lyase activity of the same P450c17 enzyme (Miller 2002). Sulfotransferase (SULT2A1) 
catalyzes the sulfonylation of DHEA to DHEAS, which has a more stable plasma level due to 
the longer half-life in blood and less fluctuating secretion (Rosenfeld et al. 1975). DHEAS is 
secreted by the adrenal cortex only and not by the gonads (Nieschlag et al. 1973). 
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Figure 1. Steroidogenesis in the human adrenal cortex. Cholesterol enters the mitochondia 
with assistance of the steroidogenic acute regulatory protein (StAR). The horizontal and vertical 
lines represent enzymes that are expressed in a zone-specific pattern. Arrows indicate the 
direction of the metabolic pathway. P450scc, cholesterol side-chain cleavage enzyme; P450c17, 
17α-hydroxylase/17,20-lyase; SULT2A1, dehydroepiandrosterone sulfotransferase; 3βHSD, 
3β-hydroxysteroid dehydrogenase; P450c21, 21-hydroxylase; P450c11, 11β-hydroxylase/18-
hydroxylase/18-oxidase; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone 
sulfate. Modified from (Miller 1988).  
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The levels of enzymes needed for steroid production directly regulate the secretion of adrenal 
androgens, which cannot be stored as lipid-soluble steroids in the adrenal cortex (Miller 2008). 
P450c17 has both 17α-hydroxylation and 17,20-lyase activities, of which only 17α-
hydroxylation is required for glucocorticoid synthesis, and neither of them is needed for 
mineralocorticoid production (Figure 1). The discrimination between 17α-hydroxylation and 
17,20-lyase activities is regulated by serine phosphorylation of P450c17 (Zhang et al. 1995) and 
the allosteric action of cytochrome b5 (Auchus et al. 1998, Akhtar et al. 2005), both of which act 
to optimize the interaction of P450c17 with its electron donor, P450 oxidoreductase. The 
abundant expression of P450 oxidoreductase and cytochrome b5 increases the 17,20-lyase 
activity in the zona reticularis, whereas the low expression of 3β-hydroxysteroid dehydrogenase 
(3ßHSD), which competes for substrates with P450c17 diverts the steroidogenesis further to the 
production of androgens (Kelnar and Brook 1983, Endoh et al. 1996, Gell et al. 1998, Dardis et 
al. 1999, Suzuki et al. 2000). The activity of SULT2A1 also increases in the zona reticularis by 
the time of adrenarche (Suzuki et al. 2000). In vitro studies on mouse Y-1 adrenocortical cells 
have shown that SF-1 regulates the expression of several steroidogenic genes, e.g. P450scc, 
StAR and 3ßHSD (Parker and Schimmer 1997), whereas DAX-1 represses their expression 
(Zazopoulos et al. 1997, Lalli et al. 1998). 
 
2.1.2 Regulation of adrenarche 
 
Adrenarche precedes gonadarche, i.e., the activation of gonadal hormone secretion, and these 
events are regulated separately (Dhom 1973, Rosenfield et al. 1982, Apter and Vihko 1985). 
Patients with precocious puberty exhibit gonadarche in the absence of adrenarche (Sklar et al. 
1980, Counts et al. 1987), and adrenarche progresses normally despite the treatment aiming at 
the pituitary-gonadal suppression in these children (Wierman et al. 1986, Palmert et al. 2001). 
In addition, patients with gonadal dysgenesis or isolated gonadotropin deficiency have a normal 
onset of adrenarche (Albright et al. 1942, Sizonenko and Paunier 1975, Sklar et al. 1980, 
Counts et al. 1987). The regulation of adrenal androgen production has been summarized in 
simplified form in figure 2. 
   The pituitary gland secretes ACTH, which stimulates adrenal glucocorticoid and androgen 
production in a circadian rhythm (Nieschlag et al. 1973, de Peretti and Forest 1976). Without  
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Figure 2. The regulation of adrenal androgen production from the zona reticularis and 
the target tissues of circulating adrenal androgens. The transcription factors DAX-1 and SF-
1 are essential for the development of the adrenal gland. Genes and environmental factors form 
the basis for the regulation of adrenal androgen production, in which factors such as Wnt4, 
adrenocorticotropic hormone (ACTH), insulin, insulin-like growth factor 1 (IGF-1) and leptin 
participate. The innermost layer of the adrenal cortex, called the zona reticularis, secretes 
adrenal androgens that have effects on e.g. the pilosebaceus unit, bone and brain. 
 
the action of ACTH, a rise in the adrenal androgen secretion cannot happen. The lack of 
adrenarche in the patients with familial glucocorticoid deficiency syndrome due to ACTH 
resistance provides evidence for a significant role of ACTH in the regulation of adrenarche 
(Sizonenko and Paunier 1975, Weber et al. 1997). ACTH mediates the effects on 
steroidogenesis through a membrane receptor called melanocortin-2 receptor (MC2R), the 
activation of which increases intracellular cAMP level, leading to the stimulation of synthesis 
and activity of StAR and the steroidogenic enzymes:P450c17, 3βHSD, SULT2A1 (McAllister 
and Hornsby 1988, McCarthy and Waterman 1988). Besides these effects on steroidogenesis, 
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ACTH is essential for the maintenance and growth of steroidogenic cells in the adrenal cortex 
(Dallman 1984). The hypothalamo-pituitary-adrenal axis regulates its own functions by a long 
feedback; glucocorticoids inhibit the secretion of corticotropin releasing hormone (CRH) in the 
hypothalamus, and this inhibits the secretion of ACTH from pituitary gland (Watts 2005). 
However, there are no significant changes seen in the circulating cortisol and ACTH levels 
during adrenarche (Apter et al. 1979). In addition, DHEA and DHEAS levels are normal for 
both chronological and bone age in most children and adolescents with Cushing's disease 
(Hauffa et al. 1984). It has been proposed that factors like prolactin, estrogens, or CRH could 
modulate the actions of ACTH in the zona reticularis cells (Ibáñez et al. 1999b, Baquedano et 
al. 2007), but no convincing mechanisms for these hypotheses have been found. Intra-adrenal 
factors such as the sympatho-adrenal system and cytokines have also been suggested to 
participate in the initiation of adrenarche (Ehrhart-Bornstein et al. 1998, l'Allemand and Biason-
Lauber 2000). 
   An interaction between adrenal androgens and serum cytokines, IGF-1, and insulin has been 
postulated in adrenarche (Belgorosky et al. 2009), as all these factors have gender-dependent 
changes during puberty. In cultured fetal adrenocortical cells, IGF-2 is expressed in response to 
ACTH, and it promotes the production of cortisol and DHEAS by increasing the expression of 
P450scc and P450c17 (Voutilainen and Miller 1987, Mesiano et al. 1997), whereas IGF-1 
increases the expression of P450c17 and 3βHSD in cultured adult adrenocortical cells 
(l'Allemand et al. 1996, Kristiansen et al. 1997). Serum DHEAS levels correlate positively with 
serum IGF-1 in prepubertal girls, whereas no correlation has been found in girls during puberty 
or in boys before and during puberty (Guercio et al. 2002, Guercio et al. 2003). These results 
have been suggested to indicate sexual dimorphism in the regulation of adrenarche, in which 
IGF-1 may regulate adrenal progenitor cell proliferation and migration (Baquedano et al. 2005). 
On the other hand, insulin resistance and compensating hyperinsulinemia occur during puberty 
(Moran et al. 1999), and plasma insulin concentrations correlate positively with IGF-1 levels 
(Bloch et al. 1987). Plasma insulin levels also correlate with serum DHEAS levels in pubertal 
children, but not in prepubertal children with adrenarche (Bloch et al. 1987, Smith et al. 1989). 
Decreased insulin sensitivity is related to serum growth hormone concentrations and body fat 
during puberty (Amiel et al. 1986, Travers et al. 1995, Moran et al. 1999). The possible role of 
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insulin sensitivity and BMI in adrenarche is not straightforward and may be gender-dependent 
(Guercio et al. 2002, Guercio et al. 2003).  
   Obese children have elevated adrenal androgen levels compared to lean children (Denzer et 
al. 2007), and body weight correlates positively to adrenal androgen levels in normal-weighted 
prepubertal children (Ong et al. 2004). The timing of adrenarche has been connected with the 
most rapid rise in BMI during longitudinal follow-up (Remer and Manz 1999). Leptin 
stimulates 17,20-lyase activity of P450c17 in vitro, possibly by affecting on the 
phosphorylation of the enzyme (Biason-Lauber et al. 2000), but no relationship between leptin 
and DHEAS levels are found in boys during puberty (Mantzoros et al. 1997). In contrary to the 
current body weight, adrenal androgen levels are inversely related to birth weight in both boys 
and girls. It has been suggested that higher adrenal androgen secretion could contribute to the 
links between early catch-up growth and adult disease risks, possibly by enhancing insulin 
resistance and central fat deposition (Ong et al. 2004).   
   Many studies have indicated a role of genetic regulation in adrenal androgen secretion. A 
significant genetic component has been determined with a heritability of 58% in the weight-
adjusted adrenal androgen excretion rate in a study on monozygotic and dizygotic twins with 
the mean ages of 11.3 and 8.7 yrs, respectively. Environmental factors account for 17% of the 
variation in the adrenal androgen production, and their role may be more important in girls than 
in boys (Pratt et al. 1994). Besides the age- and gender-dependent variation of adrenal androgen 
levels, there is a significant genetic component in the residual variation of serum DHEAS levels 
in adults (Rotter et al. 1985, Yildiz et al. 2006). In addition, there is significant heterogeneity in 
the secretion of DHEA in response to ACTH, whereas there is little inter-subject variability in 
the cortisol secretion (Azziz et al. 2001).  
   It may be speculated that the expression patterns of many genes are different between the 
zona fasciculata and reticularis. The first microarray study on 750 genes found 17 genes whose 
expression differed significantly between the two zones. Several genes that are expressed at 
higher levels in the zona reticularis encode components of the major histocompatibility 
complex and enzymes involved in peroxide metabolism. The same study confirmed earlier 
results: 3βHSD is expressed at a very low level in the zona reticularis, whereas the expression 
of SULT2A1 is higher in the zona reticularis than in the zona fasciculata (Wang et al. 2001). In 
comparison of the adult adrenal cortex with the fetal cortex, the microarray study on thousands 
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of transcripts showed higher expression of IGF-1 and 3βHSD in the adult cortex, in addition to 
many genes with an unknown role in the adrenocortical function (Rainey et al. 2001). The 
search for factors regulating the expression of steroidogenic enzymes is continuing. For 
example, transcription factors such as the orphan nuclear receptor called estrogen related-
receptor α, SF-1 and GATA-6 have been found to enhance the expression of SULT2A1 (Saner 
et al. 2005, Seely et al. 2005). 
   From an evolutionary perspective, genes must have a central role in the regulation of 
adrenarche. Adrenarche is a recent event in human evolution, as only the chimpanzee exhibits 
adrenarche comparable to that of man (Cutler et al. 1978). Rhesus macaques experience 
morphological changes parallel to fetal zone regression during the first three months of life, 
resulting in the differentiation of the innermost zona reticularis which lacks 3ßHSD, but 
exhibits increased cytochrome b5 expression (Nguyen et al. 2008). Interestingly, female rhesus 
macaques exposed in utero to exogenous androgen excess developed features of 
hyperandrogenism and metabolic disorders that are similar to polycystic ovary syndrome 
(PCOS) in humans (Abbott et al. 2005). Variation in the CYP17 gene encoding P450c17 has 
been examined as an explanation of the evolution of adrenarche in higher primates, but such 
variation does not exist (Arlt et al. 2002). The lack of appropriate animal models has hampered 
the research on the regulation of adrenarche (Abbott and Bird 2009).  
 
2.2 PREMATURE ADRENARCHE 
 
2.2.1 Definition, clinical features and long-term sequelae 
 
The clinical phenotype varies in subjects with PA. The androgenic signs include premature 
pubarche and axillary hair (Silverman et al. 1952, Thamdrup 1955), oily hair and skin 
(Rosenfield et al. 1982), adult-type sweating and body odor (Voutilainen et al. 1983, Kaplowitz 
et al. 1986, Likitmaskul et al. 1995) (Table 1). Most studies have shown only transient effects 
of PA on growth and maturity. The growth of children with PA may be accelerated, which can 
be seen already before other androgenic signs (Silverman et al. 1952, Likitmaskul et al. 1995, 
Pere et al. 1995). The bone age is often slightly advanced (Silverman et al. 1952, Ibáñez et al. 
  
 23 
1992, Balducci et al. 1994, Likitmaskul et al. 1995), and PA subjects have higher bone mineral 
content and density than controls when adjusted for age, weight, height, and fat mass (Sopher et 
al. 2001). The final height of PA subjects is not significantly reduced, however (Pere et al. 
1995), and it may be even above midparental height (Ibáñez et al. 1992). PA is followed by 
normal-timed gonadarche (Silverman et al. 1952, Ibáñez et al. 1992), or PA girls may reach 
menarche somewhat earlier than the maternal and population menarcheal age (Pere et al. 1995).  
 
Table 1. Clinical features of premature adrenarche. 
 
Symptoms Growth of pubic or axillary hair 
Oily hair 
Comedones and acne 
Adult-type sweating and body odor 
Age Girls < 8 yrs and boys < 9 yrs 
Findings Adrenal androgens elevated for chronological age  
     e.g. serum DHEAS ≥ 1 µmol/l 
Growth may be accelerated 
Bone age may be slightly advanced 
Prevalence 0.8 – 2.8% 
Differential diagnosis Adrenal tumors 
Steroidogenic enzyme defects 
Precocious central puberty 
  
   PA is caused by the early maturation of zona reticularis resulting in increased adrenal 
androgen secretion for chronological age (Dhom 1973). The adrenarcheal minimum level of 
DHEAS has been set at 1 µmol/l (40 µg/dl) (Rosenfield et al. 1982). However, pubic hair 
appears at variable DHEAS levels above that and even at lower levels, while the other adrenal 
androgens may be elevated (Rosenfield et al. 1982, Kaplowitz et al. 1986, Lashansky et al. 
1991, Likitmaskul et al. 1995). Some investigators have defined exaggerated adrenarche by the 
basal or ACTH-stimulated adrenal androgen levels above the normal adrenarcheal levels 
(Granoff et al. 1985, Lucky et al. 1986, Likitmaskul et al. 1995, Rosenfield 2007).  
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   The incidence of premature adrenarche is unknown. It can be assumed that many children 
with PA do not visit the doctor or child welfare clinics. The prevalence of pubic hair before the 
age of 8 yrs is 2.8% in white American girls (Herman-Giddens et al. 1997), whereas it is only 
0.8% in Lithuanian girls (Zukauskaite et al. 2005). The prevalence of PA is higher among girls 
than boys with a ratio around 10:1 (Silverman et al. 1952, Thamdrup 1955). The prevalence 
varies in different populations, and PA is more common in black people (Kaplowitz et al. 
1986). African-Americans also enter puberty earlier than white children. Black girls reach 
Tanner stage II for breast development at the mean age of 8.9 yrs, compared with white girls at 
10.0 yrs, and boys reach Tanner stage 2 for genital growth at the mean age of 9.5 and 10.1 yrs, 
respectively. Similarly, the mean ages at stage II for pubic hair development in Africa-
American and white girls are 8.8 yrs and 10.5 yrs, respectively, and in boys, 11.2 yrs and 12.0 
yrs (Herman-Giddens et al. 1997, Herman-Giddens et al. 2001).  
   In the differential diagnosis of PA, adrenal tumors, steroidogenic enzyme defects and central 
precocious puberty are to be kept in mind (Silverman et al. 1952). The first papers describing 
PA reported a high proportion of PA children having cerebral dysfunction (Silverman et al. 
1952, Thamdrup 1955, Rosenfield et al. 1982), while later reports have concentrated on 
otherwise healthy children. Children with moderate to severe cerebral palsy (CP) have earlier 
pubarche (at a mean age of 8.2 yrs) than healthy girls (10.5 yrs), and to a lesser extent this can 
also be seen in boys (10.7 yrs vs. 11.9 yrs, respectively). Advanced sexual maturation associates 
with high body fat in girls with CP, but with low body fat in boys with CP (Worley et al. 2002). 
   In last decades, PA has been connected with adverse features. Children with PA have been 
found to have hyperinsulinemia, alterations in the IGF system, an unfavorable lipid profile and 
higher BMI. Lean Catalan girls with PP have higher mean serum insulin values during an oral 
glucose tolerance test (OGTT) before and throughout puberty than controls. Furthermore, 
increased IGF-1 levels and decreased SHBG and IGF binding protein 1 (IGFBP-1) levels have 
been reported in most of these girls (Ibáñez et al. 1997a). A study on Caribbean Hispanic and 
African-American girls with PA showed nearly half of them to have reduced insulin sensitivity 
in response to an intravenous glucose tolerance test with tolbutamide. ACTH-stimulated 
androgen levels were higher in those girls with reduced insulin sensitivity, most of whom were 
also obese and had acanthosis nigricans (Vuguin et al. 1999). In line with these two studies, 
predominantly obese Hispanic prepubertal PA girls had elevated free IGF-1 levels, that 
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correlate with adrenal androgens in the insulin-resistant subset of these girls (Silfen et al. 
2002a). Many studies have indicated clearly increased BMI in PA children in comparison to 
age-matched healthy controls (Vuguin et al. 1999, Silfen et al. 2002a, Charkaluk et al. 2004), 
and a study on normal weighted Catalan PP girls has shown increased central fat mass in 
comparison to selected controls with similar BMI (Ibáñez et al. 1998a, Ibáñez et al. 2003a). 
Independently of BMI, Catalan PP girls had higher triglycerides levels and higher ratio of low-
density lipoprotein (LDL) to high-density lipoprotein (HDL) (Ibáñez et al. 1998a). Other 
studies, however, have failed to find significant differences in the lipid pattern (Meas et al. 
2002). Furthermore, prepubertal PA children have differences in their psychological and 
cognitive functions compared with children who have normal-onset adrenarche, which suggest 
them to be more vulnerable to various psychopathologies (Dorn et al. 1999).  
   Already in the 1960s, PA was described in the literature to precede PCOS (Wilkins 1965). 
This concept was supported by studies on postmenarcheal PP girls with oligomenorrhea and 
increased incidence of functional ovarian hyperandrogenism (FOH) determined by higher 
gonadotropin-releasing hormone (GnRH) agonist-stimulated 17-hydroxyprogesterone (17OHP) 
levels (Ibáñez et al. 1993). In addition, increased 17-hydroxypregnenolone and DHEA 
responses to GnRH agonist stimulation have been observed during pubertal development in 
Catalan PP girls, suggesting increased ovarian activity of P450c17 (Ibáñez et al. 1997b). On the 
other hand, increased 17-hydroxypregnenolone response to ACTH stimulation has been found 
in premenarcheal Caribbean Hispanic and African American girls with PA (Banerjee et al. 
1998), as well as in a small group of white and black American PP girls, in whom no difference 
in the response to GnRH agonist stimulation was observed (Mathew et al. 2002). The results 
have been interpreted to mean that PA increases the risk for PCOS, suggesting common 
pathogenic mechanisms (Kousta 2006, Witchel 2006, Ibáñez et al. 2009). In a heterogeneous 
group of PA girls, exaggerated adrenarche was suggested to carry an increased risk for PCOS, 
although the risk may vary with the clinical and hormonal characteristics of the particular study 
population (Rosenfield 2007). No large longitudinal studies with efficient power have been 
conducted to confirm the theory that PA precedes PCOS. 
   Endocrine programming during fetal life may play a role in the regulation of adrenarche. 
There is an inverse correlation between birth weight and prepubertal adrenal androgen levels in 
healthy children, whereby the catch-up growth is correlated with serum adrenal androgens 
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(Francois and de Zegher 1997, Ong et al. 2004). The mean birth weight of Catalan PP girls has 
been reported to be about 1 SDS lower than in healthy controls, and the difference is even 
larger in postmenarcheal PP girls with and without FOH (Ibáñez et al. 1998b). A retrospective 
study on Australian PA girls revealed an increased proportion of subjects with a history of 
prematurity or being born small for gestational age (SGA) (Neville and Walker 2005). Studies 
on SGA children show higher DHEAS levels at the age of 12 yrs and after menarche (Ibáñez et 
al. 1999c, Tenhola et al. 2002). A continuum of adverse development rabging from prenatal 
programming to premature adrenarche and later on to PCOS has been postulated (van 
Weissenbruch 2007, Ibáñez et al. 2009). However, a French study on post-menarcheal PP girls 
failed to find a link between PP and either low birth weight or insulin resistance, although a 
higher risk for hirsutism and modest hyperandrogenism in girls with PP was shown (Meas et al. 
2002). 
   The incidence of PA is lower in boys, and the clinical outcomes seem to differ in comparison 
to girls with PA. A small study on Hispanic boys with PP did not find any difference in insulin 
sensitivity, IGF-1 or SHBG levels or in birth weight between PP boys and their bone age- and 
pubertal stage-matched controls before and during puberty (Potau et al. 1999). However, a 
small study on an ethnically heterogeneous group of prepubertal boys found higher IGF-1, but 
lower SHBG levels and decreased insulin sensitivity in PA boys independent of BMI (Denburg 
et al. 2002). 
   It has been debated whether PA children should be followed routinely into adulthood and 
would they benefit from therapeutic interventions (Rosenfield 2007, Ibáñez et al. 2009). PA 
children have some metabolic characteristics that imply a higher risk for the impaired glucose 
metabolism and cardiovascular complications. Furthermore, PA girls may be at a higher risk for 
developing PCOS and infertility. Both anti-androgen flutamide and insulin-sensitizing 
metformin have been used with success in preliminary studies on PA girls during and after 
puberty to reduce androgen levels, fat mass, hyperinsulinemia and cholesterol levels, and 
further improve the features of FOH (Ibáñez et al. 2000b, Ibáñez et al. 2000c, Ibáñez et al. 
2008). There are no studies on the benefits of interventions such as exercise and diet in children 
with PA, which could be essential in preventing the increase of BMI and the worsening of 
glucose metabolism.  
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2.3 GENETIC VARIATION 
 
The genetic code is stored in genomes, which vary between species and between individuals, 
and are differently regulated from cell to cell. Resolving the whole genome sequences of 
different species has made it possible to determine how evolution has shaped the human 
genome. Determining the genetic variation between individuals has opened up the possibility to 
associate genotype with phenotype. Finding out the mechanisms behind the regulation of gene 
expression is opening our eyes to the complexity of gene expression in different organs, tissues 
and cells at different time points in the lifespan in response to different stimuli from the inner 
and outer world. 
 
2.3.1 Variation of the human genome 
 
The structure of the human genome offers the platform for genetic variation. The size of the 
human genome reaches three billion base pairs, and only around one percent of it represents the 
22500 genes coding proteins (International Human Genome Sequencing Consortium 2004). 
When the sequence of nearly the whole human genome was reported for the first time in 2001, 
a surprising amount of non-coding elements was revealed (Lander et al. 2001, Venter et al. 
2001). The factors that have separated humans from other eukaryotes, multicellular organisms 
and vertebrates lie not in the number of base pairs or in the number of protein coding genes, but 
in the non-coding sequences, including introns, regulatory elements and transposable elements. 
Segmental duplications, gene duplications, recombinations and mutations during replication 
have been driving forces in genetic evolution.  
   Genetic variation makes every human genome individual, leading to an ever-different 
phenotype. The human genome project and the sequencing of three individual human genomes 
have revealed up to four million single nucleotide polymorphisms (SNPs) and a huge amount of 
structural variants (Levy et al. 2007, Bentley et al. 2008, Wheeler et al. 2008). A SNP is defined 
as a change of one nucleotide to another of the three possibilities in at least 1% of all humans. 
Common SNPs have a minor allele frequency (MAF) of more than 5%. The density of SNPs 
varies in the sequence. On average, human genome has a SNP in every 1–1.9 kb 
(Sachidanandam et al. 2001, Bentley et al. 2008). Structural variation covers insertions, 
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deletions, inversions, duplications and translocations, encompassing copy-number variants. 
Structural variants range from small insertion/deletion events to segmental duplications, and 
from more than one base pair to a few million base pairs in length. An integrated map of genetic 
variation for eight human genomes defines the location of 1695 sites of structural variation (> 6 
kb in length) and 796273 small insertion/deletions (1-100 bp in size) (Kidd et al. 2008). 
Structural genetic variation covers a much larger proportion of the whole human genome than 
SNPs. SNPs result in different amino acids of encoded proteins, different regulation of gene 
expression and different splicing sites for RNA processing, or they may have no effect (Hull et 
al. 2007). Structural genetic variation can confer phenotypes through many mechanisms, 
including gene dosage and unmasking functional SNPs on the remaining allele (Human 
Genome Structural Variation Working Group et al. 2007). The goal of mapping all the sequence 
variation in the human genome is the understanding of the genotype-phenotype associations, the 
mechanisms of diseases and the individual responses to treatments. 
   Candidate gene analyses have been used to determine a possible association between the 
phenotype or disease and variation in a gene that is important for the condition. However, many 
reported associations have never been replicated after the first reports (Lohmueller et al. 2003). 
The international HapMap project was established in 2003 to determine the amount and linkage 
of common human sequence variation (International HapMap Consortium 2003). Since then, 
most of the SNPs have been described, and information on linkage disequilibrium patterns of 
the SNPs has been collected in the public databases. Tagging SNPs are used to locate genetic 
variation behind complex traits in genome wide association studies (GWA), which have 
successfully discovered loci and genes that could have never been suspected to be associated 
with disease when using the candidate gene approach based on the biochemical and molecular 
knowledge of the day. Population isolates, like the Finns, have higher linkage disequilibrium 
with less variation in the genome between subjects, offering advantages for GWA studies on 
complex traits (Varilo and Peltonen 2004). New biochemical and bioinformatics methods are 
needed not only to determine more precisely the biochemical basis of mechanisms between 
genetic variation and molecular networks, but also to evaluate gene-environment 
interconnections. 
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2.3.2 Variation in gene expression 
 
Every somatic cell has the same genome with all the variants in an individual combination 
characteristic in each human being. Gene expression is regulated in every cell in a tissue-
specific manner. Thus, genetic variants may have different effects in different cells based on the 
cell-specific regulation. 
 All the steps of gene expression are regulated by multiple mechanisms (Orphanides and 
Reinberg 2002). Gene expression begins with chromatin structure modifications, enabling 
transcription initiation and ends with posttranslational modifications of encoded proteins. 
Humans have around 3000 transcription factors that participate in the regulation of transcription 
and interact with each other by silencing and enhancing the transcription. The promoter regions 
for the binding of transcription factors may be large and located far from the coding exons 
(Levine and Tjian 2003). For example, steroid hormones bind to nuclear receptors, and these 
complexes works as transcription factors by binding with DNA response elements and altering 
the transcription rate of the target genes (Perissi and Rosenfeld 2005). Transcribed mRNA is 
processed before translation, introns are spliced out, and alternative splicing sites may be used 
to get different proteins. At this stage, microRNA molecules can silence gene expression by 
degradation of mRNA molecules.  
   In addition, epigenetics involve heritable mechanisms that regulate gene expression. 
Epigenetic mechanisms are not stored in the genomic sequence, but in the chromatin structures 
and histone modifications (Bjornsson et al. 2004). X-chromosome inactivation involves 
epigenetic mechanisms that mostly silence one of the two X-chromosomes into transcriptionally 
inactive highly condensed heterochromatin in each female cell to compensate for gene dosage. 
X-inactivation occurs shortly after the implantation of female embryos or during the induction 
of cell differentiation, and the maintenance of stable X-inactivation requires synergistic actions 
of several epigenetic mechanisms: coating of the X-chromosome by Xist RNA, DNA 
methylation and histone modifications (Heard and Disteche 2006).   
   Interaction of promoter region, genes, microRNAs, chromatin remodeling and other factors 
form complex networks (Phillips 2008). We are still at the beginning on our way to understand 
the genetic regulation of complex traits and polygenic diseases. 
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2.4 GENES IN PREMATURE ADRENARCHE 
 
The pathogenesis of PA was discussed in the literature before physiological adrenarche was 
described. It is unequivocal nowadays that premature adrenarche results from the early 
development of the zona reticularis, secreting increased amounts of androgens for the 
chronological age (Silverman et al. 1952, Thamdrup 1955, Conly et al. 1967). Like the 
regulation of physiological adrenarche, the pathogenesis of premature adrenarche remains 
obscure. Factors such as obesity, hyperinsulinemia and increased IGF-1 levels may participate 
in the regulation of PA, and the process may begin with prenatal programming.  
   Genes have been demonstrated to have an essential role in PA, with polygenic effects on 
heterogeneous phenotypes. A linkage analysis study on three families with either PP or 
adolescent hyperandrogenism found difficulties in classifying family members as affected or 
unaffected, and ended with conclusions that the condition is multifactorial, with several genes 
contributing to the condition and distinct susceptibility genes may be present in various families 
(Sanders et al. 2002). Several candidate gene studies have searched for susceptibility variants in 
genes involved in steroidogenesis, androgen action and metabolism (Table 2).  
 
2.4.1 Genes in steroidogenesis and androgen action 
 
The genes encoding steroidogenic enzymes have been tempting targets as candidates for the 
genetic regulation of PA. Defects in CYP21 and CYP11 encoding P450c21 and P450c11, and in 
3βHSD can cause a PA-like condition with variable signs of virilization (Marui et al. 2000). 
Before the development of sequencing methods, enzyme activities were calculated from 
responses to ACTH stimulation, and many more defects in steroidogenesis were found than 
could be confirmed by sequencing the coding regions of CYP21 and 3βHSD later on (August et 
al. 1975, Morris et al. 1989, Oberfield et al. 1990, del Balzo et al. 1992, Hawkins et al. 1992, 
Siegel et al. 1992, Balducci et al. 1994, Chang et al. 1995, Sakkal-Alkaddour et al. 1996). Non-
classical congenital adrenal hyperplasia (CAH) due to mutations in CYP21 and 3βHSD can be 
ruled out in PA children by measurements of basal 17OHP and 17-hydroxypregnenolone levels, 
respectively, and if those are moderately elevated, by performing an ACTH stimulation test 
(Leite et al. 1991, Likitmaskul et al. 1995, Mermejo et al. 2005). The frequency of CYP21 
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mutations leading to non-classical CAH varies between populations, and is relatively high in 
Hispanics and Italians (Speiser et al. 1985). In Finland, non-classical CAH due to CYP21 
mutations is rare (Jääskeläinen et al. 1997). 
   All the polymorphisms and mutations reported in children with PA have been shown in Table 
2. Heterozygote carriers of CYP21 mutations have been reported with an increased frequency 
varying from 35% to 37.5% in PA subjects of American and Hellenic origin, whereas no 
increased frequency has been reported in Catalan PP girls. However, no clinical parameter has 
been linked to the heterozygosity of CYP21 mutations in subjects with PA (Dacou-Voutetakis 
and Dracopoulou 1999, Witchel et al. 2001, Potau et al. 2002). Heterozygous carriers of 3βHSD 
mutations have been found in 7.5% of the American PA children, but the mutations did not 
associate with the phenotype, either. Forty two % of these American PA children had mutations 
in either or both of the CYP21 and 3βHSD genes, whereas only 6.6% of a sample of women 
without PA had a variant in these genes. Surprisingly, five of the six PA boys were 
heterozygous carriers of CYP21 mutations (Witchel et al. 2001).  
   Adrenal steroids are synthesized in the zona reticularis, but peripheral target tissues 
metabolize them. DHEAS can be converted back to DHEA and further to Δ4-A, testosterone 
and dihydrotestosterone (DHT), and from Δ4-A to estrogens. 17β-Hydroxysteroid 
dehydrogenase (HSD17B5) catalyzes reactions including the conversion of Δ4-A to 
testosterone and DHEA to androstenediol. No HSD17B5 genotype was associated with PP or 
testosterone levels, when one SNP in the promoter region of HSD17B5 and three exonic SNPs 
were analyzed (Petry et al. 2007). CYP19 encodes aromatase enzyme that catalyzes the 
conversion of androgens to estrogens. The genotype distribution is different according to 
SNP50 in the coding region of CYP19 between Catalan PP girls and controls. The major variant 
homozygote A/A is more frequent in the PP girls, in whom the A/A genotype is associated with 
higher testosterone and DHEAS levels and decreased insulin sensitivity when adjusted for 
pubertal stage (Petry et al. 2005). However, the haplotype with G allele in the SNP50 was 
associated with an increased probability of PP and further development of FOH in the 
haplotype analysis that was based on four tagging SNPs, suggesting that another variant in the 
haplotype may be the causal variant (Petry et al. 2005). In the distal promoter region of CYP19, 
SNP43 was associated with testosterone levels in the same Catalan cohort, but no genotype was 
associated with an increased risk for PP (Petry et al. 2006). Increased 5α-reductase and 11β-
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hydroxysteroid dehydrogenase activities could influence adrenal androgen levels in target 
tissues by producing DHT from testosterone and by reducing the conversion of cortisol to 
inactive  cortisone, respectively, but no differences in their activities based on urinary steroid 
metabolites have been observed in prepubertal PA girls (Silfen et al. 2002b). Glucuronidation 
by the UDP-glucuronyltransferase 2B (UGT2B) is one mechanism through which androgens 
are inactivated, but no differences have been found between PP children and healthy controls in 
the allele frequencies of UGT2B variant associated with lower Vmax of the enzyme (Tomboc and 
Witchel 2003). Recently, Noordam et al. identified heterozygous inactivating mutations in the 
gene encoding human 3’-phosphoadenosine-5’-phosphosulfate (PAPS) synthase 2 in a girl with 
PP, hyperandrogenic anovulation, very low DHEAS levels, and increased androstenedione and 
testosterone levels. PAPS is required for the catalytic activity of SULT2A1 that converts DHEA 
to DHEAS, and the observations on the patient highlighted the crucial role of DHEA sulfation 
as a gatekeeper to human androgen synthesis (Noordam et al. 2009). 
   Increased sensitivity of hair follicles to adrenal androgens has been postulated as a possible 
pathogenic mechanism for PA since Silverman et al. reported in the first paper on PA that PA 
subjects have variable levels of adrenal androgens, overlapping with those in normal children 
(Silverman et al. 1952). The androgen receptor gene (AR) contains a highly polymorphic region 
with a variable number of CAG repeats (CAGn) encoding a polyglutamine tract, the length of 
which has an inverse relationship with the transcriptional activity of AR (Chang et al. 1988, 
Lubahn et al. 1988, Chamberlain et al. 1994, Beilin et al. 2000). Two studies have demonstrated 
that Mediterranean girls with PP have a mean CAGn about one repeat shorter than healthy 
controls, indicating that they have more active ARs (Ibáñez et al. 2003b, Vottero et al. 2006). In 
addition, the shorter AR gene CAGn has been associated with an increased risk of subsequent 
FOH in the Catalan PP girls (Ibáñez et al. 2003b). Vottero et al. studied AR gene methylation 
and found that the methylation pattern in the pubic hairs of Italian prepubertal PP girls was 
similar to girls with Tanner stage II (Vottero et al. 2006), but the role of AR gene methylation in 
the receptor activation and androgen sensitivity has not been examined in more detail. 
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2.4.2 Genes in metabolism 
 
Children with PA have hyperinsulinemia, higher BMI and an impaired lipid profile, and their 
first-degree relatives often have cardiovascular risk factors. The parents of Catalan PP girls 
have an increased prevalence of type 2 diabetes mellitus (T2DM) and impaired glucose 
tolerance accompanied with an unfavorable lipid profile, compared with the overall prevalence 
of T2DM and impaired glucose tolerance in Catalonia. Furthermore, hyperandrogenism and 
gestational diabetes mellitus are frequent among the mothers of PA girls (Ibáñez et al. 1999a). 
Interesting theories about the connection between hyperinsulinemia and hyperandrogenemia 
suggest that hyperinsulinemia may precipitate hyperandrogenemia in vulnerable individuals by 
unmasking latent abnormalities in the regulation of steroidogenesis, or it may be a marker of a 
more fundamental abnormality that affects multiple systems (Rosenfield 1996). 
   Genetic variation in several genes participating in insulin-IGF signaling or body weight 
regulation has been studied mainly in two cohorts of PA children: Catalan PP girls during and 
after puberty, and American PP girls and boys. Variation has been explored in genes encoding 
proteins at various steps of insulin-IGF-signaling: insulin, insulin receptor substrate-1 (IRS-1), 
sorbin and SH3-domain-containing protein (SORBS1) involved in insulin-mediated glucose 
uptake, and type 1 IGF receptor (IGF-1R). Genetic variation associating with insulin resistance 
and higher BMI has been studied in genes encoding plasminogen activator inhibitor-1 (PAI-1), 
glutamate decarboxylase 2 (GAD2), glucocorticoid receptor, and β3-adrenergic receptor and 
melanocortin-4 receptor (Table 2). A polymorphism in IGF-1R has a different genotype 
distribution between PA children and controls. Variants in the insulin gene and IRS-1 have been 
associated with differences in the PA phenotype, but variation in SORBS1 has not been 
associated with PA or phenotype of PA (Ibáñez et al. 2001, Witchel et al. 2001, Ibáñez et al. 
2002, Tomboc and Witchel 2003, Roldan et al. 2007). 
   The minor variant G at SNP E1013E in IGF-1R has been associated with higher circulating 
IGF-1 levels (Bonafe et al. 2003). In PP children, the frequency of this minor variant is 
increased (Roldan et al. 2007). The variant does not relate to clinical measures, however, 
although IGF-1 was not measured in the study (Roldan et al. 2007). Interestingly, all six PP 
boys studied were either heterozygotes or homozygotes for the minor variant at SNP E1013E 
(Roldan et al. 2007).  
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   A variable number of tandem repeats (VNTR) in the insulin gene relates to the transcription 
levels of the insulin gene (Le Stunff et al. 2000). In Catalan PP girls, the class I genotype of 
VNTR has been associated with lower birth weight and reduced insulin sensitivity in agreement 
with previous studies, but there was no difference in the genotype distribution between PP girls 
and age- and BMI-matched controls. VNTR class I allele and low birth weight had additive 
effects on hyperinsulinemia and dyslipidemia in these PP girls (Ibáñez et al. 2001).  
   The minor variant at G927R of IRS-1 impairs insulin signaling (Almind et al. 1993). Among 
the Catalan PP girls heterozygous for the minor variant of G927R, SHBG concentrations were 
lower than in those homozygous for the major variant. The frequency of the minor variant was 
twice as high in PP girls who later developed FOH as in healthy control girls, although IRS-1 
genotype was not a significant predictor for the development of FOH in the regression model 
with significant effects of age, insulin, LDL cholesterol and IGFBP-1 levels (Ibáñez et al. 
2002). In the American PP cohort, the G927R variant in IRS-1 and T228A at SORBS1 have not 
shown significantly different genotype distributions from controls, nor have there been 
associations with clinical parameters (Witchel et al. 2001, Tomboc and Witchel 2003).  
   The 4G/5G insertion/deletion polymorphism in the promoter of PAI-1 has been related to 
circulating PAI-I levels and inconsistently with insulin resistance and cardiovascular disease 
(Eriksson et al. 1995, Panahloo et al. 1995, Viitanen et al. 2001). The genotype distribution of 
the 4G/5G polymorphism did not differ between Catalan PP girls and controls. In post-
menarcheal PP and control girls, the 5G allele was associated with insulin resistance (Lopez-
Bermejo et al. 2007). The minor variant of rs2236418 in the promotor of GAD2 was associated 
with morbid obesity in the initial case-control study of 1200 subjects (Boutin et al. 2003), but 
further studies have not been able to replicate the result (Swarbrick et al. 2005, Groves et al. 
2006). In the American PP girls, the minor G variant was associated with an increased BMI at 
both initial and follow-up visits, but the genotype distribution of PP girls was not compared 
with that of healthy controls (Witchel et al. 2009). Genetic variations in the genes encoding the 
glucocorticoid receptor, β3-adrenergic receptor, and melanocortin-4 receptor have not shown an 
association with PA (Table 2) (Witchel et al. 2001, Martin et al. 2004).  
   Taken together, the minor variants of SNP E1013E at IGF-1R and G927R at IRS-1 may 
underlie PP by increasing IGF-1 levels and decreasing SHBG levels, respectively, whereas the 
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VNTR genotype of insulin gene may provide a link between low birth weight and 
cardiovascular risk factors in PP girls.  
 
2.4.3 Candidate genes in the current study 
 
The hypotheses for associations of PA with following candidate genes were based on the 
knowledge of PA and earlier described genetic variants in these genes (Figure 3). 
 
2.4.3.1 MC2R 
 
ACTH has an essential role in the regulation of adrenarche (Weber et al. 1997). Genetic factors 
may explain heterogeneity in adrenal secretion of DHEA in response to ACTH  (Azziz et al. 
2001). The ACTH receptor is a G protein-coupled membrane receptor that belongs to the 
melanocortin receptor family and is called the melanocortin-2 receptor (MC2R) (Buckley and 
Ramachandran 1981, Gantz and Fong 2003). In the human MC2R gene, one intron separates the 
coding exon 2 from the upstream untranslated exon 1 (Naville et al. 1997). A SNP has been 
described within the transcription initiation site at position – 2 bp, altering the consensus 
sequence from T to C (MC2R -2 T>C). The minor variant of MC2R -2 T>C results in lower 
promoter activity in vitro due to changes in transcription initiation, and it is associated with 
lower cortisol and DHEA secretion in response to ACTH stimulation in vivo (Slawik et al. 
2004, Reisch et al. 2005).  
 
2.4.3.2 AR 
 
The development of pubic hair is dependent on the interplay between the plasma androgen level 
and other biologic factors that affect the response of the pilosebaceous unit to androgens 
(Rosenfield 1994). One of the suggested biologic factors is the androgen receptor (AR), through 
which the androgens mediate their effects. The ligand-bound AR binds to regulatory DNA 
elements in the promoter region of target genes to influence the transcription rate through 
interaction with cofactors and transcription machinery (Perissi and Rosenfeld 2005). The length 
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of the CAGn repeat in exon 1 of the X-chromosomal AR gene has an inverse relationship with 
the transcriptional activity of AR (Chamberlain et al. 1994, Beilin et al. 2000). Previous studies 
have demonstrated that girls with PP have a shorter mean CAG repeat in the AR than healthy 
controls (Ibáñez et al. 2003b, Vottero et al. 2006), but none of these studies has taken X-
chromosome inactivation into account. Methylation of HpaII sites close to the AR gene CAGn 
region correlates with X-inactivation (Allen et al. 1992).  
 
 
Figure 3. The positions of the candidate genes in the regulation of adrenarche. The 
melanocortin 2-type receptor (MCR2R) mediates the effects of adrenocorticotropin (ACTH). 
The androgen receptor (AR) mediates the effects of adrenal androgens on target tissues. Low-
density liporotein receptor-related protein 5 (LRP5) and transcription factor 7-like 2 (TCF7L2) 
participate in Wnt signaling. The fat mass and obesity associated (FTO) gene has been 
connected with obesity, and body weight is correlated with increased circulating adrenal 
androgen levels. 
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2.4.3.3 LRP5 and TCF7L2 
  
Both low density lipoprotein receptor-related protein 5 (LRP5) and transcription factor 7-like 2 
(TCF7L2) are factors in WNT signaling that is essential for embryogenesis, postnatal 
development and tissue homeostasis (He et al. 2004), and which has an active role in the 
development and function of adrenal glands (Kim et al. 1998, Suwa et al. 2003, Kim et al. 
2008). In humans, loss-of-function mutations in WNT4 have been described in the autosomal 
recessive SERKAL syndrome with female to male sex reversal and renal, adrenal and lung 
dysgenesis (Mandel et al. 2008), and also in women with the Mayer-Rokitansky-Küster-Hauser-
like syndrome associated with Müllerian-duct regression, virilization and high androgen levels 
(Biason-Lauber et al. 2004, Philibert et al. 2008). Wnt4 represses steroidogenesis in the adrenal 
cortex and gonads based on the studies on transgenic Wnt4 mice (Jordan et al. 2003, Heikkilä et 
al. 2005). 
   LRP5 is a single-span transmembrane receptor belonging to the low-density lipoprotein 
receptor family (Hey et al. 1998). LRP5 and its homologue LRP6 act as Wnt co-receptors (He 
et al. 2004). Common polymorphic variants in LRP5 have been shown to contribute to bone 
density in different populations and various age groups (Koay et al. 2004, Mizuguchi et al. 
2004, Ferrari et al. 2004, Kiel et al. 2007, Koay et al. 2007, Saarinen et al. 2007). In the 
canonical WNT signaling, Wnt molecules bind to their receptors co-acting with LRP5 on cell 
membrane, which leads to the inactivation of β-catenin degradation intra-cellularly, resulting in 
increased the amounts of β-catenin. Downstream in the canonical WNT signaling pathway are 
TCF transcription factors that together with β-catenin activate WNT target gene expression. In 
the absence of β-catenin, TCFs bind to target gene promoters and repress their expression (Jin 
2008). The genetic variants of TCF7L2 have been previously associated with type 2 diabetes 
(Grant et al. 2006, Cauchi et al. 2007, Wang et al. 2007) and an increased risk for early 
impairment of glucose metabolism in obese children (Körner et al. 2007). 
 
2.4.3.4  FTO 
 
PA is associated with increased BMI (Vuguin et al. 1999, Silfen et al. 2002a, Charkaluk et al. 
2004), and it is well known that healthy obese children have elevated adrenal androgen levels 
 
 39 
compared with lean children (Denzer et al. 2007). Genetic variants in the fat mass and obesity 
associated gene (FTO) have been associated consistently with obesity (Dina et al. 2007, 
Frayling et al. 2007, Grant et al. 2008). Each risk allele increases weight around 1.5 kg in 
adults, and the homozygote carriers of the risk alleles have 1.67-fold increased odds of obesity 
(Frayling et al. 2007). The association reflects an increase in fat mass that is observed from 
early infancy on, but not at birth (Frayling et al. 2007, Grant et al. 2008, Lopez-Bermejo et al. 
2008). The FTO risk genotype correlates with dysregulation of glucose and lipid metabolism to 
an extent consistent with its effect on BMI (Frayling et al. 2007, Do et al. 2008, Freathy et al. 
2008). The effect of genetic variants at FTO can be compensated by regular sports (Rampersaud 
et al. 2008), whereas low physical activity accentuates the effect of the risk variant on body fat 
accumulation (Andreasen et al. 2008). In addition, FTO is expressed in the human 
hypothalamus, pituitary and adrenal gland, suggesting a potential role in the hypothalamic-
pituitary-adrenal axis implicated in body weight regulation (Su et al. 2004, Dina et al. 2007). 
However, the function of FTO remains largely unknown. 
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3 AIMS OF THE STUDY 
 
The study was conducted to determine the role of genetic variation of PA candidate genes in a 
case-control cohort of prepubertal PA children and their age- and gender-matched controls. 
Genotype distributions between the groups were compared and single marker association 
analyses were used to relate genetic variants with the clinical phenotype. 
 
Five candidate genes were studied: 
 
1) MC2R gene encoding the ACTH-receptor, which has an essential role in 
adrenarche and the individual response of adrenal androgen production to ACTH 
(I) 
 
2) AR gene and X-chromosome inactivation, because low adrenal androgen levels 
have been observed in PA children, suggesting higher androgen sensitivity (II) 
 
3) LRP5 and TCF7L2 genes, because of their role in Wnt signaling in adrenal cortex 
and in metabolic functions (III, IV) 
 
4) FTO gene, because it is associated with obesity, and body weight correlates 
positively with adrenal androgen levels in healthy prepubertal children (IV). 
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4 SUBJECTS AND METHODS 
 
This study on genetic variation in prepubertal PA is a part of a longitudinal follow-up study on 
a case-control cohort of PA children with the entire clinical spectrum of androgenic signs and 
their age- and gender-matched controls collected by Pauliina Utriainen, MD, Jarmo 
Jääskeläinen, MD, PhD, and Raimo Voutilainen, MD, PhD (Utriainen et al. 2007, Utriainen et 
al. 2009a, Utriainen et al. 2009b). The clinical evaluation of study subjects, hormonal 
assessments and genotyping methods have been described in detail in the original publications 
(I-IV).   
 
4.1 CASE-CONTROL COHORT 
 
The study group was comprised of 171 prepubertal Caucasian children from the Northern Savo 
district in Eastern Finland. For the subjects with PA, the criteria for entry into the study were 
any clinical sign(s) of adrenarche, including pubic or axillary hair, acne, adult-type body odor 
or oily hair before the age of 8 yrs in girls and 9 yrs in boys independent from the DHEAS 
levels. All eligible children were invited to the study between October 2004 and January 2006. 
Seventy-six eligible children were found, and 74 (97.4%) of them were willing to participate 
(64 girls and 10 boys). One girl with signs of central puberty in addition to PA was included in 
the analysis of genotype distribution of the polymorphism in MC2R promoter (I), but excluded 
from all the other analyses (63 girls and 10 boys; I, II, III and IV). Steroidogenic enzyme 
defects and virilizing tumors were excluded biochemically and by adrenal ultrasonography. 
Altogether 97 healthy age- and gender-matched healthy controls (79 girls and 18 boys) were a 
random sample of children from the same district, obtained from the Finnish population 
register, and approximately 20% of the control children invited were willing to participate. At 
examination, girls in both groups had to be less than 9 yrs and boys less than 10 yrs of age. 
Children with central puberty, any endocrine disorder or long-term medication were excluded 
from both groups. The study protocol was approved by the Research Ethics Committee of 
Kuopio University Hospital. Informed written consent from parents and assent from children 
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were obtained for participation in the study, including collection and genotyping of DNA 
samples. 
   The appearance time of the adrenarcheal signs was obtained by interviewing the parents. 
Clinical examination of all the children was performed by the same physician (Pauliina 
Utriainen) to determine the androgenic signs and exclude centrally activated puberty. Birth 
weight, birth length and gestational age data were obtained from hospital records. The birth 
measures were converted to SD scores (SDS) by plotting them on the growth charts and 
adjusting the birth measures for gender and duration of gestation (Pihkala et al. 1989). Height 
was measured with a calibrated Harpenden stadiometer to the nearest 0.1 cm. Weight was 
measured in thin underwear to the nearest 0.1 kg and converted to percentages in relation to the 
median weight-for-height according to the national reference values (Sorva et al. 1990). BMI 
was calculated according to the formula [weight (kg) / height2 (m)], and BMI SDS was 
determined by British reference values (II) (Cole et al. 1995). Blood pressure (BP) was 
measured with a standard sphygmomanometer from the left arm in supine position after a 30-
min rest in bed and recorded as the average of three repeated measurements. 
   For the endocrine-metabolic assessment, baseline levels of plasma glucose, triglycerides, total 
cholesterol, LDL and HDL cholesterol, and serum insulin, cortisol, DHEAS, DHEA, Δ4-A, and 
SHBG were measured after an overnight fast between 0900 and 1000 h from all subjects. For 
all the children, ACTH stimulation tests were performed administering synthetic ACTH 1-24 
(Synacthen; Novartis Pharma GmbH, Nürnberg, Germany) 1 ug/1.73 m2 i.v. Serum samples for 
cortisol, DHEA, Δ4-A, and 17OHP were taken 30 min after the ACTH administration. An oral 
glucose tolerance test (OGTT) was performed by administering 1.75 g/kg glucose (max 75 g) to 
each subject with samples for plasma glucose and serum insulin analyses taken at 30, 60, 90 
and 120 min.  Hormonal assays are described in the original publications (I and II). For the 
evaluation of insulin sensitivity, homeostasis model assessment for insulin resistance (HOMA-
IR) was calculated according to the formula: fasting plasma glucose (mmol/l) * fasting serum 
insulin (mU/l) / 22.5 (Allard et al. 2003), and insulin sensitivity index (ISIcomp) was calculated 
according to the formula: 10 000 / √ [fasting glucose (mg/dl) * fasting insulin (µU/l) * mean 
glucose (mg/dl) * mean insulin (µU/l)] (Matsuda and DeFronzo 1999). 
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4.2 GENOTYPING METHODS 
 
DNA was isolated from whole blood samples using the Wizard Genomic DNA Purification Kit 
(Promega, Madison, WI). The genetic variants were genotyped using restriction fragment 
length analysis (I), TaqMan Allelic Discrimination Assays® (IV) and by direct sequencing of 
the gene (III). The variants and genotyping methods are described in Table 3. 
 
Table 3. Genetic polymorphisms analyzed and the methods used in genotyping. 
 
Gene Chromo-
somal 
location 
Polymorphism Position Genotype Genotyping 
method 
Orig. 
publ. 
MC2R 18p11.2 MC2R -2 T>C -2 from the 
transcription 
initiation site  
T/C RFLP I 
AR Xq11.2 CAGn Exon 1 CAGn PCR, automated 
electrophoresis 
II 
LRP5 11q13.4 19 SNP Exons, introns, 
3’UTR 
 Direct 
sequencing 
III 
TCF7L2 10q25.3 rs7903146 Intron 3 C/T TaqMan Assay® IV 
TCF7L2 10q25.3 rs12255372 Intron 4 G/T TaqMan Assay® IV 
FTO 16q12.2 rs9939609 Intron 1 T/A TaqMan Assay® IV 
MC2R, melanocortin-2 receptor; LRP5, lowdensity lipoprotein receptor-related protein 5, TCF7L2 transcription factor 
7-like 2; FTO, fat mass and obesity associated gene; SNP, single nucleotide polymorphism; UTR, untranslated region; 
RFLP, restriction fragment length polymorphism based on polymerase chain reaction (PCR) and SacI enzyme 
digestion. 
 
CAG repeat length was determined by automated fluorescence detection, and the X-
chromosome inactivation assay was based on the AR gene methylation (II) (Allen et al. 1992). 
HpaII sites close to the AR gene CAGn are methylated on the inactive X-chromosome. 
Methylation-sensitive restriction enzyme HpaII digests only the unmethylated (active X-
chromosome) DNA, which is thereby unavailable for the following PCR amplification. Both 
digested and undigested DNA samples were amplified by PCR, and the PCR products were run 
on denaturing gel as in the genotyping analysis. To compensate for the unequal amplification of 
alleles, values for the digested samples were normalized with those for the undigested samples 
with calculations for shorter allele with formula (p1d/p1u) / (p1d/p1u + p2d/p2u), in which p1d 
and p2d represent the peak areas (p) of HpaII-digested (d) alleles (1 and 2), and p1u and p2u are 
the corresponding peak areas of the undigested (u) alleles (Lau et al. 1997). Methylation 
weighted biallelic means of CAGn (mwCAGn) were achieved by multiplying each allele in a 
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genotype pair by its percentage of total expression (100 minus inactivity %) and summing the 
two adjusted repeat values (Hickey et al. 2002). Individuals homozygous at the AR gene CAGn 
locus (9 controls and 1 PA subject) and boys were included in the mwCAGn analyses, because 
variation in the allele expression would not alter the mean value of alleles of equivalent repeat 
number or the mean of one allele. Skewing of X-chromosome inactivation was determined as 
80% or higher for the activity of one allele (Naumova et al. 1996).  
 
4.3 STATISTICAL ANALYSES 
 
Fisher's exact test (I-III) and test for equality of proportions (IV) were used to test for 
differences in genotype groups and MAFs between the control and PA groups. For single 
marker association analyses Student's t-test (II, IV), Mann-Whitney U-test (I-IV), ANOVA (IV) 
and Kruskall-Wallis (IV) tests were used to compare clinical parameters between genotype 
groups, while univariate linear model (III, IV) and multiple linear regression (II) were used to 
test for differences adjusted for age and gender, or other factors. The difference between the 
arithmetic mean of CAGn and the mwCAGn was tested with paired samples t-test (II). The 
strength of the relationship between mwCAGn and the clinical measurements was estimated by 
Kendall's rank correlation, because it offers both a meaningful estimate of the strength of the 
relationship and the statistical significance (II). The results are presented as means with 95% 
confidence intervals (CI), if not otherwise stated. In the case of skewed distribution, raw data 
were log-transformed prior to using the tests with assumptions of normal distribution, and 
results are presented as geometric means with 95% CI. For measures remaining non-normally 
distributed after log-transformation, non-parametric tests were used. No corrections for multiple 
testing were performed. We tried to limit the problem of multiple testing by restricting the 
analyses to the most important measures only. P < 0.05 was considered statistically significant. 
Statistical analyses were performed with SPSS 14.0 statistical package (SPSS Inc., Chicago, IL) 
and test for equality of proportions and power calculations were conducted with R statistical 
program, version 2.7.2 (IV) (http://www.r-project.org/). Hardy-Weinberg equilibrium was 
calculated according to standard procedures using χ2 test (I, III, IV). Linkage disequilibrium 
between the LRP5 or TCF7L2 polymorphisms was analyzed with Haploview4.0 (III, IV) 
(Barrett et al. 2005). 
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5 RESULTS AND DISCUSSION 
 
5.1 CHARACTERISTICS OF THE CASE-CONTROL COHORT 
 
Pauliina Utriainen et al. have reported the clinical data of the cohort (Utriainen et al. 2007, 
Utriainen et al. 2009a, Utriainen et al. 2009b). Thirty-five (48%) of the 73 PA children were 
recorded to have PP with the presence of pubic or axillary hair (PP), whereas 38 PA children 
(52%) had other androgenic signs (nonPP). Nine PA subjects had serum DHEAS concentrations 
below 1 µmol/l, and 36 of the 97 control subjects had DHEAS at or above 1µmol/l at the time 
of evaluation. Only one PA subject had exaggerated adrenarche defined as basal serum DHEAS 
concentration exceeding 6 µmol/l. None of the PA subjects had non-classical 21-hydroxylase 
deficiency based on the baseline and ACTH-stimulated 17OHP levels (Utriainen et al. 2009a). 
 
Table 4. Clinical and hormonal characteristics in children with premature adrenarche (PA) as 
compared to healthy age- and gender-matched controls. 
 
Mean (95% CI) Variable 
Control 
n = 97 
PA  
n = 73 
P value* 
Gender (boys/girls) 18/79 10/63  
Age (yr) 7.5 (7.3-7.7) 7.5 (7.2-7.7)        0.8 
Birth weight (SDS) 0.2 (-0.04-0.4) -0.03 (-0.3-0.2)        0.2 
Birth length (SDS) 0.3 (0.1-0.5) -0.05 (-0.3-0.2) 0.04 
Weight-for-height (%)  102 (93-111)** 108 (93-123)**       0.004** 
BMI (SDS) 0.4 (0.2-0.6) 1.0 (0.7-1.3)   0.001 
Height (SDS) 0.3 (0.1-0.5) 1.2 (0.9-1.4) <0.001 
DHEAS (µmol/L)† 0.8 (0.7-0.9) 1.7 (1.5-2.0) <0.001 
Δ4-A (nmol/L)† 1.3 (1.2-1.5) 2.4 (2.1-2.7) <0.001 
SHBG (nmol/L) † 102 (96-108) 82 (73-90) <0.001 
Cholesterol (mmol/L)  4.2 (4.1-4.4) 4.2 (4.1-4.4)        0.9 
HOMA-IR† 0.9 (0.8-1.0) 1.1 (1.0-1.2)   0.002 
ISIcomp 1.1 (1.0-1.2) 0.8 (0.7-0.9) <0.001 
Systolic BP (mmHg) 100 (98-102) 105 (102-107)   0.004 
CI, confidence interval; SDS, SD score; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; Δ4-A, 
androstenedione HOMA-IR; homeostasis model assessment for insulin resistance according to the formula: fasting 
plasma glucose (mmol/l) x fasting serum insulin (mU/l) / 22.5; ISIcomp, insulin sensitivity index according to the 
formula: 10 000 / √ [fasting glucose (mg/dl) x fasting insulin (µU/l) x mean glucose (mg/dl) x mean insulin (µU/l)]; BP, 
blood pressure  
* Values taken from Student’s t-test unless indicated otherwise 
** Median (interquartile range), analyzed with Mann-Whitney U-test 
† Raw data were log-transformed prior to using the t-test, and results are presented as geometric means with 95% CI. 
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   Gender distribution and mean age were similar between the PA and control groups (Table 4). 
PA subjects had higher weight-for-height, BMI and current height, whereas there were no 
significant differences in the birth measures. Adrenal androgens were significantly higher in the 
PP subjects and nonPP subjects than in the control subjects (Utriainen et al. 2007). There was 
no difference in the lipid profile between the groups. The differences in the androgen and 
SHBG levels and in ISIcomp remained significant when adjusted for BMI, whereas the 
significance of the difference in HOMA-IR and systolic BP disappeared (P = 0.06 and 0.2, 
respectively). 
5.2 GENOTYPE DISTRIBUTIONS 
 
5.2.1 MC2R, LRP5, TCF7L2 and FTO 
 
SNP MC2R -2 T>C, SNPs rs7903146 and rs12255372 in TCF7L2 and rs9939609 in FTO were 
genotyped in the 73 PA children and the age- and gender matched 97 control subjects (I, IV, 
Table 5). Nineteen SNPs were found in LRP5 in the total group of 170 children. Eleven SNPs in 
LRP5 were synonymous and four were non-synonymous exonic variants, of which five SNPs 
had MAF over 5% in either group (Figure 1 in III, Table 5). Three intronic SNPs and one SNP 
in the 3’ untranslated region of LRP5 were also identified. Eleven SNPs in LRP5 had MAF 
lower than 5% in both control and PA group, but none were found to be a likely disease-causing 
mutation (III). All of the genotyped SNPs were in Hardy-Weinberg equilibrium with a P-value 
> 0.05 (I, III, IV). 
   There were no statistically significant differences in the genotype distributions or in the 
MAFs of the SNPs in MC2R, LRP5, TCF7L2 and FTO between the PA and control groups (I, 
III, IV, Table 5). However, the minor variant in MC2R -2 T>C was more frequent in the PP 
children than in nonPP and control children, suggesting its role in the development of PA 
[controls n = 97, nonPP n = 38 vs. PP n = 36; combined T/C&C/C frequency; 10%, 11% vs. 
28%, P = 0.04, I]. The obesity risk-conferring variant at rs9939609 of FTO was not more 
frequent in the PA children despite their higher BMI, compared with healthy controls. 
Furthermore, the 95% CI for differences in the minor allele proportions showed a tendency for 
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the risk variant of rs9939609 to be less frequent in the PA children than in the population-based 
age-matched prepubertal controls (IV, Table 5). 
 
Table 5. The genotype distributions and differences in minor allele frequencies of common 
single nucleotide polymorphisms (SNP) among prepubertal children with premature adrenarche 
(PA) and healthy age- and gender-matched controls. 
  
Gene SNP Genotype distribution  
(A/A, A/a, a/a; %) 
P 
  Control  
(n = 97) 
PA 
(n = 73) 
Difference in MAF  
(95% CI) 
*/** 
MC2R MC2R -2 
T>C 
90, 10, 0 81, 18, 1# 0.05 (-0.01 - 0.11) 0.2/0.1 
LRP5 F549F 94, 6, 0 86, 14, 0 0.04 (-0.02 - 0.09) 0.1/0.2 
 E644E 89, 11, 0 90, 10, 0 -0.01 (-0.06 - 0.04) 0.8/0.9 
 N740N 91, 9, 0 86, 14, 0 0.02 (-0.03 - 0.08) 0.5/0.5 
 V1119V 74, 25, 1 64, 36, 0 0.05 (-0.03 - 0.13) 0.2/0.3 
 A1330V 91, 9, 0 88, 12, 0 0.02 (-0.04 - 0.07) 0.6/0.7 
TCF7L2 rs7903146 73, 26, 1 67, 30, 3 0.03 (-0.05 - 0.12) 0.5/0.4 
 rs12255372 72, 26, 2 70, 27, 3 0.01 (-0.07 - 0.10) 0.9/0.8 
FTO rs9939609 32, 50, 18 41, 45, 14 -0.06 (-0.18 - 0.05) 0.5/0.3 
MC2R, melanocortin-2 receptor; LRP5, low density lipoprotein receptor-related protein 5, TCF7L2 transcription factor 
7-like 2; FTO, fat mass and obesity associated gene.  
*, P value from Fischer’s exact test on the differences in the genotype distributions; **, P value for the difference in 
minor allele proportions; #, total n = 74. 
 
Reliable haplotype analyses expanding the whole LRP5 gene could not be performed, because 
the haploview analysis revealed only one small LD block (D' 1.000, r2 0.30) between the 
intronic rs4988322 and the exonic V1119V. However, the control children with the minor 
variant at A1330V also had the minor variant at N740N, whereas there was one PA subject with 
the minor variant at N740N but not at A1330V (III). LD between the rs7903146 and 
rs12255372 at TCF7L2 was high (r2 = 0.82, D' 0.90). Therefore, we tested only rs7903146 in 
the single marker association analyses (IV). 
   Although our PA group is among the largest ones reported, the power of our study to 
demonstrate small differences in the genotype distributions was limited. The two groups with a 
total of 170 children provided only 14% and 11% power to detect the observed differences in 
the proportions of minor alleles at rs9939609 of FTO and rs7903146 of TCF7L2, respectively 
(α = 0.05). To show a statistical difference at the observed differences in the proportions of 
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minor alleles at rs9939609 and rs7903146 with 80% power (α = 0.05), we would have needed 
892 and 1383 subjects in the PA and control groups, respectively (IV).  
 
5.2.2 Length of CAG repeat in the androgen receptor gene and X-
inactivation 
 
Children with PA had an arithmetic mean AR CAGn 0.72 repeats shorter than the controls (95% 
CI for the difference; 0.09-1.34, P = 0.025), and the mean difference in mwCAGn was even 
larger [0.76  (0.14-1.38), P = 0.017), II]. None of the PA subjects had mwCAGn longer than 25 
repeats, whereas nine controls had (Figure 1 in II). The arithmetic mean and mwCAGn differed 
significantly from each other in the whole group of children, indicating the importance of 
considering X-inactivation in the analyses of X-chromosomal genes (II). The results confirmed 
the finding of a similar difference in the arithmetic mean of CAGn between the Catalan PP girls 
and controls (Ibáñez et al. 2003b). Although the difference of 0.8 repeats in AR gene mwCAGn 
between the PA and control groups is small, its clinical relevance may be considerable. The 
meta-analysis of the studies on the association of male infertility with AR gene CAGn has 
revealed a statistically significant difference of 0.3 repeats between the cases and controls 
(Davis-Dao et al. 2007). The longitudinal follow-up of our PA girls will show whether the 
length of AR gene CAGn is inversely related to the risk of ovarian hyperandrogenism as 
observed in the Catalan PP girls (Ibáñez et al. 2003b). 
   We did not find any differences between our control and PA groups in the incidence of 
nonrandom X-inactivation (proportion of subjects with either maternal or paternal allele being 
inactive in ≥ 60% of cells; 35% controls vs. 39% PA, P = 0.7) or skewed X-inactivation 
(inactive ≥ 80%; 1.7% controls vs. 3.3% PA, P > 0.9), suggesting no significant role of X-
inactivation itself in the pathogenesis of PA (II). In contrast, a small previous study in Italian 
women with idiopathic hirsutism has shown skewing of X-inactivation, leading to preferential 
expression of the AR gene with shorter CAGn (Vottero et al. 1999). The results on Italian 
women with hirsutism also conflict with a larger Spanish study demonstrating neither skewing 
of X-inactivation nor difference in mean CAGn length between women with hyperandrogenic or 
idiopathic hirsutism and healthy controls (Calvo et al. 2000). We were not able to investigate X-
inactivation in peripheral target tissues, but an excellent study comparing the X-inactivation 
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between different tissues has shown a similar X-inactivation pattern in blood cells and other 
tissues (Bittel et al. 2008).  
   We observed a weak correlation between the mwCAGn and subject’s age in the PA group (τ = 
0.27, P = 0.026, II). X-inactivation offers a possible epigenetic mechanism through which 
environmental factors may influence gene expression (Heard and Disteche 2006), but the 
mechanisms leading to secondary skewing of X-inactivation are not fully understood. A 
previous study has shown greater variability in X-inactivation in women older than 60 yr (Bittel 
et al. 2008). In addition, X-inactivation patterns have been shown to differ between sister pairs 
having the same genotype, but different clinical presentation in the families with PCOS (Hickey 
et al. 2006).  
 
5.3  ASSOCIATIONS BETWEEN GENOTYPE AND PHENOTYPE 
 
The associations between genotype and phenotype were searched by single marker association 
analyses on the common genetic variants at MC2R, AR, LRP5, TCF7L2 and FTO in the PA and 
control groups. In the following, the results will be presented and discussed according to 
adrenocortical functions, anthropometric data and metabolic parameters. Of the SNPs in LRP5, 
SNP E644E was not associated with any clinical measures in the control or the PA group (III). 
As the control children with SNP A1330V also had the SNP N740N, their results for the SNP 
N740N were the same as for SNP A1330V that leads to an amino acid change (III). 
   The value of these studies lays in the precise phenotyping of PA subjects and unbiased 
controls, that all come from a homogenous population. However, our results should be 
confirmed in other populations with different genetic backgrounds and different environments, 
and by large genome-wide association studies. It is possible that some of the observed 
associations are by chance only, as the number of children in our study was relatively small. 
Further studies are required to determine the functional significance of the polymorphisms 
genotyped. The biochemical mechanisms are not fully understood for them, i.e., how they affect 
the gene expression or the functions of encoded proteins. 
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5.3.1 Adrenocortical function 
 
The circulating levels of adrenocortical hormones and SHBG of the PA children have been 
summarized according to genotype groups in Table 6. There was no difference in the age 
between the genotype groups (I, III, IV).  
 
5.3.1.1 MC2R 
 
PA children with minor variant at MC2R -2 T>C had higher baseline plasma ACTH, serum 
DHEA and Δ4-A levels in comparison to the PA subjects with the T/T genotype (I). The 
statistically significant difference remained in the baseline Δ4-A level when the difference was 
adjusted for age and gender (P = 0.02, Table 6) Among the controls, the baseline hormone 
levels did not differ between the MC2R genotype groups. As an indicator of ACTH sensitivity, 
the baseline ACTH/cortisol ratio was calculated and it was significantly higher in the subjects 
with the T/C or C/C genotype than in the T/T subgroup of control children (I), which is in 
accordance with the previously reported higher ACTH/cortisol ratio among healthy adult men 
with C allele (Slawik et al. 2004). Recently, the minor variant at MC2R -2 T>C was shown with 
increased frequency in patients with infantile spasms, and it was associated with poor response 
to the ACTH therapy (Liu et al. 2008). 
   As an indicator of shifting steroidogenesis from glucocorticoids to adrenal androgens, we 
calculated the ratio of cortisol level to Δ4-A level, which was lower in the children with the T/C 
or C/C genotype than in those with the T/T genotype when all children were analyzed together 
[T/T n = 147 vs. T/C&C/C n = 23; ratio of cortisol level to Δ4-A level; mean (95% CI); 169 
(152-185) vs. 114 (86-142), P = 0.008, I]. Indicated by the altered cortisol/Δ4-A ratios in the 
children with the C allele, it is possible that decreased ACTH sensitivity due to MC2R -2 T>C 
polymorphism shifts the adrenal steroidogenesis from the cortisol synthesis to the androgen 
pathway. It has been postulated that in times of critical or chronic illness, steroid synthesis is 
diverted from adrenal androgens to glucocorticoids to allow maintenance of high glucocorticoid 
levels that are crucial for coping with the illness (Parker et al. 1985, Bornstein and Chrousos 
1999). Thus, the mechanism in PA would be the opposite to the stressful states in critical and 
chronic illness, and even in functional hypothalamic amenorrhea, in which plasma adrenal 
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androgens are decreased and cortisol levels are increased (Luppa et al. 1991, Beishuizen et al. 
2002, Bomba et al. 2007, Dimopoulou et al. 2007).  
 
5.3.1.2 AR mwCAGn 
 
One of our hypotheses was that increased androgen sensitivity would be a mechanism for PA in 
children with adrenal androgen levels normal for their age. However, we did not find any 
inverse correlation between AR mwCAGn and androgen or SHBG levels, nor did we find any 
significant difference in mwCAGn between the children with DHEAS level below 1µmol/l or 
above that level, representing biochemical adrenarche (II). Our results are in contrast to the 
study on post-menarcheal Catalan PP girls in whom higher testosterone levels and more 
pronounced signs of hyperandrogenism were observed in girls with a mean CAGn of less than 
20 repeats (Ibáñez et al. 2003b). Our results suggest that AR gene CAGn has no role in the 
feedback regulation of adrenal androgen secretion in prepubertal children with PA. 
 
5.3.1.3 LRP5, TCF7L2 and FTO 
 
No minor variant of the SNPs at LRP5, TCF7L2, or FTO were associated with adrenal androgen 
levels in the PA children when adjusted for age and gender. The baseline serum cortisol level 
was lower in the PA subjects with the minor variant of F549F at LRP5 than in those without, 
but no differences were found in serum cortisol concentrations measured after ACTH 
stimulation, and no similar association was observed in the control group (III). In the control 
children, the minor variants of A1330V and N740N at LRP5 were associated with higher 
DHEAS level (A/A vs. A/a; mean, 0.8 vs. 1.4 µmol/l, P = 0.01), but no association with other 
androgen levels or the cortisol level was observed (III). Even though the control children with 
both minor variants of SNPs A1330V and N740N did not have clinical signs of PA, their mean 
serum DHEAS concentration was > 1.0 µmol/L, which can be considered an adrenarcheal level. 
   The association between the minor variants at A1330V and N740N and serum DHEAS level 
suggests that LRP5 in the lipid metabolism of adrenocortical cells or in the canonical Wnt 
signaling may modulate the adrenal hormone profile during childhood. LRP5 in the lipid intake 
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of adrenocortical cells has not been studied, while previous studies have confirmed its role in 
the metabolism of lipoproteins (Kim et al. 1998, Magoori et al. 2003, Fujino et al. 2003). Wnt 
signaling has been suggested to play a role in the regulation of adrenal steroidogenesis. ACTH 
increases WNT4 expression in primary cultures of adrenocortical cells (Kuulasmaa et al. 2008), 
and adenovirus mediated WNT4 expression increases steroidogenesis and the expression of 
steroidogenic genes in cultured adrenocortical cells (Chen and Hornsby 2006). Adipocytes 
secrete Wnt molecules which induce the transcription of StAR and stimulate the steroidogenesis 
of adrenocortical cells in vitro (Schinner et al. 2007). Furthermore, the adrenal development is 
significantly compromised in the embryos with SERKAL syndrome due to a WNT4 mutation, 
indicating an important role of Wnt signaling in the adrenal development (Mandel et al. 2008). 
In transgenic mice, targeted disruption of ß-catenin impairs development and maintenance of 
adrenal cortex (Kim et al. 2008). 
   Although we did not find any association between LRP5 sequence variants or the TCF7L2 
variants and PA, Wnt signaling may nonetheless participate in the regulation of adrenarche. 
Recently, LRP5 has been shown to participate in the regulation of serotonin synthesis in 
duodenal heterochromatin cells via Wnt signaling, and serotonin acts in an endocrine fashion to 
regulate bone cell metabolism in mice (Yadav et al. 2008). On the other hand, WNT4 may 
antagonize the canonical Wnt signaling in the adrenal cortex, as Wnt4 over-expression inhibits 
testosterone synthesis in mouse testes by repressing synergism between ß-catenin and SF-1 
(Jordan et al. 2003). SF-1, in turn, is essential for the adrenal development (Luo et al. 1994, 
Achermann et al. 1999). The mechanisms of Wnt signaling may be more complicated in the 
regulation and development of adrenocortical cells than known today. 
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5.3.2 Anthropometric data 
 
The birth measures and the current weight adjusted for height of the children with PA according 
to various genotype groups have been summarized in Table 7. None of polymorphisms in LRP5 
was associated with either birth measures or current weight-for-height (Table 7, III). 
 
5.3.2.1 MC2R and birth measures 
 
The minor variant at MC2R -2 T>C was associated with lower birth weight SDS in the children 
with PA (I, Table 7). Previous studies have found an inverse correlation between birth weight 
and adrenal androgen levels in healthy children (Francois and de Zegher 1997, Ong et al. 2004), 
whereas PA and subsequent FOH have been connected with low birth weight (Ibáñez et al. 
1998b, Neville and Walker 2005). The PA children with the minor variant at MC2R -2 T>C had 
higher ACTH stimulated cortisol levels than the control children with the same genotype (I). A 
meta-analysis has demonstrated an inverse connection between birth weight and circulating 
cortisol levels at adulthood (Montfoort et al. 2005). Birth weight can be considered to picture 
the intrauterine milieu, in which some factors have restricted the intrauterine growth and well 
being of developing fetus. It can be speculated that the minor variant at MC2R -2 T>C may 
have had an influence on the stress responses of the PA children during fetal development. 
According to the Barker hypothesis, intrauterine growth restraint reprograms the development 
of cardiovascular disease risk profile at adulthood (Barker et al. 1993, Eriksson et al. 1999). The 
follow-up of our PA children will show whether the minor variant at MC2R -2 T>C is 
associated with adverse metabolic features later in life. The association between birth weight 
and MC2R -2 T>C may also reflect the higher proportion of PP children in the group of PA 
children that have the minor variant, although no statistically significant differences in birth 
weight SDS between PP, nonPP and control girls were found (Utriainen et al. 2007). 
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Table 7. Anthropometric data according to various genotype groups in the children with 
premature adrenarche. 
 
Mean (95% CI) Median (IQR) Gene 
  Polymorphism 
Genotype (n) 
Birth weight  
(SD score)* 
Birth length 
(SD score)* 
Weight-for-height 
(%)** 
MC2R T/T (60) 0.1 (-0.2 - 0.4) 0.1 (-0.2 - 0.4) 111 (94 - 128) 
  MC2R -2 T>C T/C&C/C (13) -0.6 (-1.0 - -0.2) -0.6 (-1.1 - -0.02) 104 (89 - 119) 
 P 0.04 0.06 0.5 
     
LRP5 C/C (63) -0.1, (-0.4 - 0.1) -0.1 (-0.3 - 0.2) 108 (95 - 122) 
  F549F C/T (10) 0.4 (-0.8 - 1.7) 0.1 (-1.2 - 1.3) 121 (105 - 138) 
 P 0.2 0.8 0.3 
     
  V1119V A/A (47) -0.05 (-0.4 - 0.3) -0.1 (-0.4 - 0.2) 108 (93 - 123) 
 A/G (26) -0.02 (-0.6 - 0.5) 0.1 (-0.4 - 0.6) 110 (94 - 126) 
 P >0.9 0.4 0.9 
     
  A1330V C/C (64) 0.01 (-0.3 - 0.3) -0.1 (-0.3 - 0.2) 108 (91 - 125) 
 C/T (9) -0.4 (-1.2 - 0.4) 0.1 (-0.6 - 0.9) 111 (101 - 121) 
 P 0.3 0.6 0.8 
     
TCF7L2 C/C (49) -0.04 (-0.4 - 0.3) 0.04 (-0.4 - 0.3) 112 (94 - 130) 
  rs7903146 C/T&T/T (24) -0.02 (-0.5 - 0.4) -0.05 (-0.5 - 0.4) 103 (93 - 113) 
 P >0.9 >0.9 0.2 
     
FTO T/T (30) -0.1 (-0.5 - 0.3) -0.1 (-0.5 - 0.3) 108 (94 - 122) 
  rs9939609 T/A (33) -0.1 (-0.4 - 0.3) -0.1 (-0.4 - 0.3)  107 (94 - 120) 
 A/A (10) 0.4 (-0.8 - 1.6) 0.3 (-0.8 - 1.3) 130 (116 - 144) 
 P 0.4 0.6 0.2 
CI, confidence interval; IQR, interquartile range; MC2R, melanocortin-2 receptor; LRP5, low density lipoprotein 
receptor-related protein 5, TCF7L2 transcription factor 7-like 2; FTO, fat mass and obesity associated gene. P values 
from *Student’s t-test or One-Way ANOVA, **Mann-Whitney U-test or Kruskall-Wallis non-parametric test.  
 
5.3.2.2 TCF7L2 and weight-for-height 
 
No difference in birth measures or weight-for-height between genotype groups according to 
rs7903146 of TCF7L2 was shown (Table 7). However, the frequency of minor variant at 
rs7903146 of TCF7L2 was higher in the lean PA subjects (weight-for-height under the median 
of the PA group) than in the controls with the same BMI [weight-for-height <108% respecting 
BMI < 0.79 SDS; controls, n = 65 vs. PA, n = 37; difference in MAF (95%CI); 0.12 (-0.001, 
0.23), P = 0.038, IV]. A recent GWA study on nearly 2000 diabetic patients and 3000 controls 
has found the risk variants at TCF7L2 to associate with increased risk for T2DM in the subjects 
with a lower BMI than the median BMI of the cases, whereas the risk ratio was lower in the 
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subjects with a higher BMI (Timpson et al. 2009). The study demonstrates a substantial 
etiological heterogeneity within T2DM, which is also evident within PA. 
 
5.3.2.3 FTO and weight-for-height 
 
Increased weight-for-height was evident in our PA children compared with healthy age- and 
gender matched controls. Of all genetic factors found so far, the polymorphisms at FTO have 
been connected most strongly with higher BMI (Li and Loos 2008). The difference in the 
current weight-for-height between FTO rs9939609 genotype groups was significant only in our 
healthy prepubertal children [mean weight-for-height; T/T, T/A vs. A/A; 99%, 109% vs. 112%, 
P = 0.001], but not in the children with PA (IV). The lack of association in the PA group may 
result from insufficient group size, but may also suggest that the role of genetic variation in 
FTO is minor in the regulation of increased weight-for-height in PA children. A previous study 
has found an association between increased BMI and the minor variant at rs2236418 of GAD2 
in PP children, but whether the association was present in healthy subjects was not tested 
(Witchel et al. 20098). 
   The role of FTO can be considered to be primary in the accumulation of weight, affecting 
eating behavior. In the pathogenesis of PA, the increased weight-for-height may be secondary 
or just one factor among others. The obesity-associated genetic variation at FTO has been 
connected with reduced satiety responsiveness (Wardle et al. 2008) and increased energy intake 
in prepubertal children (Cecil et al. 2008, Wardle et al. 2009). In mice, FTO is expressed most 
abundant in hypothalamic nuclei governing energy balance, and the expression is down-
regulated by fasting (Gerken et al. 2007). FTO shares sequence motifs with non-heme 
dioxygenases with a potential role in nucleic acid demethylation and epigenetic regulation 
(Gerken et al. 2007, Sanchez-Pulido and Andrade-Navarro 2007). Although associated with 
increased energy intake, the risk variants in FTO may not be connected with energy expenditure 
(Berentzen et al. 2008, Cecil et al. 2008, Speakman et al. 2008). Nonetheless, a recent extensive 
metabolic study on healthy non-obese young men showed increased energy efficiency in 
oxidative muscle fibers after exercise in homozygous carriers of the obesity-related risk allele at 
rs9939609 of FTO, suggesting that increased energy efficiency with potential mitochondrial 
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coupling could represent a key defect linking FTO to obesity (Grunnet et al. 2009).  
Furthermore, the expression of FTO is reduced in the adipocytes of transgenic obese db/db mice 
(Qi et al. 2008) and the risk variants have been associated with signs of cerebro-cortical insulin 
resistance (Tschritter et al. 2007), suggesting that other possible mechanisms in the actions of 
FTO. In contrast, the retrospective analysis of the growth pattern of our PA children has 
revealed increased height velocity during the first two years of life, which precedes the 
accumulation of weight compared with controls. These findings suggest that increased weight-
for-height is not a primary event in PA (Utriainen et al. 2009b). 
 
5.3.2.4  AR mwCAGn and BMI 
 
In our PA children, mwCAGn correlated positively to BMI SDS (II, Figure 3). After dividing 
the PA group by the median BMI (0.79 SDS), the PA children with lower BMI had a shorter 
mwCAGn than those with higher BMI, with a mean difference of 1.13 repeats (95% CI, 0.38-
1.87, P = 0.004). A similar difference in mwCAGn was found between the PA children with 
lower BMI compared with controls having the same BMI SDS (II). The results demonstrate that 
PA children with lower BMI have more active AR, which offers a tempting mechanism to 
explain PA in lean children. Hyperinsulinemia is more evident in the PA subjects with higher 
weight-for-height, and may be the key inducer of PA in them. 
   In previous studies, a positive correlation between the CAGn and body fat mass has been 
found in healthy males (Zitzmann et al. 2003, Stanworth et al. 2008), whereas no correlation 
between mwCAGn and BMI has been seen in the Australian women with PCOS (Hickey et al. 
2002). Furthermore, treatment with low-dose flutamide in combination with metformin has 
achieved a greater reduction in the adiposity of post-menarcheal PP girls with a shorter mean 
CAGn than in subjects with a mean CAGn longer than 20 repeats (Ong et al. 2007). A recent 
study on over 3300 men with age of 40-79 yrs, showed a positive correlation between CAGn 
and serum testosterone and estradiol levels. Weaker transcriptional activity of AR was 
interpreted as compensation for higher testosterone levels, and the residual phenotypic 
differences in e.g. body weight were postulated to reflect differences in the estrogen levels after 
aromatization of higher testosterone levels (Huhtaniemi et al. 2009). We cannot state whether 
adrenal androgens are metabolized to estrogens in our children with PA. 
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Figure 3. Scatter plot of BMI SDS by mwCAGn. As can we see from scatter plot figure, there 
was a positive correlation between methylation-weighted biallelic mean of the CAG repeat 
number (mwCAGn) in androgen receptor gene and body mass index SD scores (BMI SDS) with 
a coefficient of 0.19 in prepubertal children with premature adrenarche (n = 71, τ = 0.19, P = 
0.02 with Kendall’s rank correlation test). 
 
5.3.3 Metabolism  
 
Insulin and IGF-1 functions have been postulated to participate in the pathogenesis of PA. 
Adverse metabolic features have been shown in prepubertal PA children and in PA subjects 
after puberty (Ibáñez et al. 1998a, Vuguin et al. 1999, Silfen et al. 2002a, Ibáñez et al. 2003a, 
Charkaluk et al. 2004). We tested whether the polymorphisms at AR, LRP5, TCF7L2 and FTO 
are associated with measures of glucose metabolism, lipid profile and BP in prepubertal PA 
children and in healthy age- and gender-matched controls (II-IV). We did not find any 
associations between FTO rs9939609 and metabolic parameters either in the PA or the control 
group (IV). 
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5.3.3.1 AR mwCAGn and insulin sensitivity 
 
An inverse correlation between the insulin sensitivity index ISIcomp and AR gene mwCAGn was 
shown in the PA subjects (τ = -0.30, P = 0.014), but the statistical significance disappeared 
when corrected for BMI (II). The previous study in Catalan postmenarcheal PP girls has shown 
greater hyperinsulinemia in response to an OGTT in girls with a biallelic mean of CAGn shorter 
than 20 in than in those with a mean CAGn longer than 20, but no difference in HOMA was 
observed between the groups. (Ibanez et al. 2003b). In healthy adult men, CAGn has been 
positively associated with fasting insulin concentrations, independently of BMI, suggesting a 
protective role of short CAGn for cardiovascular risk factors (Zitzmann et al. 2003). The 
discrepancy between the studies may reflect population differences and the difference in age 
and sex among the studies. 
 
5.3.3.2 TCF7L2 and glucose metabolism 
 
In the lean PA subjects, there were weak trends for higher insulin resistance index HOMA-IR 
and lower ISIcomp in the subjects with the diabetes-related risk allele at rs7903146 of TCF7L2, 
suggesting a possible role of the risk variant in glucose metabolism (IV). The genetic variants at 
TCF7L2 have been associated with decreased insulin secretion, which is linked to impaired 
incretin effects and β-cell proliferation (Jin 2008). The biochemical mechanisms by which the 
genetic variation in the intron region influences the expression of TCF7L2 or WNT signaling in 
glucose metabolism remain largely unknown. The risk allele of rs7903146 was associated with 
higher fasting and 120-min blood glucose in OGTT in a cohort of 283 obese children with a 
mean age of 11.9 yr and mean BMI 2.8 SDS (Körner et al. 2007). In children and young adults 
with age at the onset of diabetes less than 25 yrs, the risk variants at rs7903146 and rs12255372 
of TCF7L2 were more frequent in the autoantibody-negative subjects than in autoantibody-
positive diabetic patients (Yu et al. 2009). The risk variant at rs7903146 was also more frequent 
in the glutamate acid decarboxylase antibody (GADA) -negative subjects with age of 15-34 yrs 
at the onset of type 1 diabetes mellitus, whereas no difference in the genotype distribution was 
found between older GADA-negative and -positive patients (Bakhtadze et al. 2008). Neither of 
the studies on autoantibody-negative and -positive diabetes patients found associations between 
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the risk variants of TCF7L2 and clinical measures at the onset of diabetes mellitus (Bakhtadze 
et al. 2008, Yu et al. 2009).  
 
5.3.3.3 LRP5, blood pressure and lipid profile 
 
The weight-for-height-adjusted BP and lipid levels did not differ between our girls with PA and 
the control girls (Utriainen et al. 2007). The previous reports on lipoprotein levels and lipid 
pattern in PA come from different populations with different ages (Ibáñez et al. 1998a, Meas et 
al. 2002, Guven et al. 2005, Andiran and Yordam 2008). The only associations between genetic 
polymorphisms and systolic BP in our series were found with the minor variant at V1119V of 
LRP5 in the PA children [A/A n = 47 vs. A/G n = 26; mean systolic BP (95% CI); 103 mmHg 
(100-105) vs. 108 mmHg (104-112), P = 0.02] and the minor variant at F549F of LRP5 in the 
control children [C/C n = 91 vs. C/T n = 6; 100 mmHg (98-102) vs. 108 mmHg (95-121), P = 
0.04, III]. LRP5 is expressed in the muscular component of large developing blood vessels, and 
the canonical Wnt signaling through LRP5 has been suggested to play a unique role in 
cardiovascular development (Wang et al. 2005). In a previous Japanese study, homozygosity for 
A1330V was associated with lower diastolic and mean BP in males (Suwazono et al. 2006b), 
but we found no association between A1330V and systolic BP in prepubertal children. 
   Higher total and LDL cholesterol levels were associated with the minor variants at A1330V, 
N740N and V1119V of LRP5 in the healthy control children (III). This finding is in line with 
the previous study in a Japanese population suggesting that the risk variant at A1330V is an 
independent risk factor for hypercholesterolemia (Suwazono et al. 2006a). LRP5 knockout mice 
display diet-induced hypercholesterolemia due to decreased hepatic clearance of chylomicron 
remnants (Fujino et al. 2003). Our results show that the association between the minor variant at 
A1330V and plasma cholesterol levels is already apparent in prepubertal children. In the PA 
children, the single marker analysis with LRP5 SNPs showed no similar associations with lipid 
profile. It is likely that the determinants of metabolic characteristics and lipid profile in children 
with PA are more complex than in healthy children. 
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5.3.4 Future perspectives and associations between androgen action, 
body weight and glucose metabolism 
 
In children with PA, androgen levels, body weight and glucose metabolism may influence each 
other. Overweight contributes to androgen levels possibly via hyperinsulinemia. On the other 
hand, androgens may alter adipose tissue mass deposition through site-specific modulation of 
preadipocyte differentiation as well as lipid synthesis and lipolysis in mature adipocytes (Blouin 
et al. 2008). In PCOS patients, who resemble PA children, a vicious circle has been suggested 
to exist whereby androgen excess favoring the abdominal deposition of fat further facilitates 
androgen secretion by ovaries and adrenals (Escobar-Morreale and San Millan 2007). Besides 
being a target of hormonal actions, adipose tissue is a major site for metabolism of sex steroids, 
including adrenal androgens (Kershaw and Flier 2004, Blouin et al. 2009). The adrenal 
androgens in PA children may be metabolized by adipose tissue to stronger androgens or 
estrogens with more potent local effects. .  
   Analysis of gene expression patterns of adipose cells in PA children would give insight to the 
role of increased weight-for-height in the pathogenesis of PA. Unfortunately, the techniques of 
adipose tissue biopsy do not currently offer ethically suitable methods to study dozens of 
prepubertal children. Recently, new gene loci associated with BMI were identified. Likely 
causal genes with unknown function are highly expressed in the central nervous system, e.g. 
transmembrane protein 18 (TMEM18) and glucosamine-6-phosphate deaminase 2 (GNPDA2) 
genes (Willer et al. 2009, Zhao et al. 2009). It could be interesting to clarify possible regulation 
of PA and adrenarche through genetic factors acting on the central nervous system. Until now, 
there have been no candidate gene studies on the role of genes acting primarily in the brain in 
children with PA. 
   Androgen action, weight regulation and insulin action do not all need to be disturbed for the 
clinical manifestation of PA. There are also lean PA subjects with higher androgen sensitivity 
and milder hyperinsulinemia (II). The retrospective analysis of the growth pattern of our girls 
with PA showed accelerated linear growth before the rise in weight-for-height when compared 
with healthy controls. At the time of PA presentation, the IGF-1 levels in these girls were 
increased compared with controls (Utriainen et al. 2009b). It may be speculated that PA 
children have hyperinsulinemia and higher IGF-1 levels already before the rise in weight-for-
height and adrenal androgen levels, but no prospective study on the development of PA has 
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been conducted. The mechanism for development of androgenic signs in children with PA, but 
with DHEAS levels below the adrenarcheal level remains to be identified. We did not find any 
difference in androgen sensitivity as estimated by AR gene mwCAGn between subjects with 
DHEAS level below and above the adrenarcheal level (II).  
   Genotype-phenotype associations may be different between girls and boys. A study on 
monozygotic and dizygotic twins revealed a significant genetic component in the weight-
adjusted adrenal androgen excretion rate. The study also suggested that the role of genetic 
regulation may be bigger in boys, whereas the role of environmental factors may be bigger in 
girls (Pratt et al. 1994). The number of boys with PA in our series is insufficient to test gender-
dependent differences in the regulation of adrenarche, but we did adjust all the associations for 
gender. Androgens are known to have gender-dependent effects, for example on adipose tissue 
in pubertal children and adults. The only longitudinal study, investigating the effects of weight 
loss on the adrenal androgen levels within 1 yr on obese children suggested that the role of body 
weight is possibly larger in girls. In that study, obese prepubertal girls losing substantial weight 
demonstrated no significant change in DHEAS levels, whereas girls without weight loss 
showed an increase. Obese prepubertal boys demonstrated a significant increase of DHEAS 
levels regardless of their weight change over the 1-yr study period (Reinehr et al. 2005). 
   Different settings and research methods are needed to clarify the regulation of PA and the 
genetic and environmental factors behind it. Larger study groups and international collaboration 
could confirm our results and define more precisely genotypes behind different phenotypes of 
PA. It is important to study the whole clinical spectrum of PA and to use unbiased controls. 
Otherwise, significant results could be missed, and wrong conclusions could be drawn. Each 
polymorphism has only a minor role in the polygenic pathogenesis, and the necessary group 
sizes will be at least ten times bigger than in our study. The large GWA studies have shown that 
the combined power of several genetic variants, including TCF7L2 and FTO, to predict the 
development of diabetes is only minor (van Hoek et al. 2008, Lyssenko et al. 2008). 
Furthermore, genetic variation explained less than 10% of the phenotypic variation in T2DM 
(Ruchat et al. 2008).  
   Although genetic studies on PA may not find strong predictors for the development of PA, 
they may be useful tools to identify factors in the genetic regulation of adrenarche. GWA 
studies and case reports of extreme types of adrenarche may find new genes behind adrenarche. 
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In addition to SNPs, structural variants and RNA interference are possible factors in the genetic 
regulation of adrenarche. To define more precisely the nature of on-time adrenarche, healthy 
children with varying age, adrenal androgen levels and androgenic signs as well as children 
with no adrenarche due to e.g. ACTH resistance may provide fruitful cohorts to explore. On the 
other hand, the pathways of steroid and glucose metabolism, the regulation of growth and the 
central regulation of puberty will be defined in more detail revealing possible factors in the 
regulation of adrenarche. Although the lack of appropriate animal model has hampered the 
research on adrenarche, the future may offer us new approaches e.g. with genetic engineering 
and stem cell cultures. 
   The clinical significance of our results on genetic variation in candidate genes MC2R, AR, 
LRP5, TCF7L2 and FTO in PA is minor, because the results do not help clinicians to estimate 
the risk of developing PA or to make decisions about the follow-up or treatments of PA 
children. Even the clinical relevance of PA itself is not clear. Although in previous studies PA 
has been associated with risks of cardiovascular disease and hyperandrogenism, large follow-up 
studies are needed to confirm the long-term sequelae. However, we have succeeded in defining 
some factors behind different phenotypes of PA. For example, the results in PA subjects with 
BMI less than the group median showed that higher androgen sensitivity and a higher 
prevalence of a diabetes-related risk variant in TCF7L2 may play a role in the pathogenesis of 
PA. The role of genetic factors in the pathogenesis may be larger in lean PA subjects.  
   Behind different phenotypes of PA, there are different genetic factors to be found together 
with different environmental factors. Follow-up studies on PA children will show how the 
different genotypes and phenotypes are related with risks of consequent disturbances in 
hormonal functions or metabolism in adulthood.  
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6 CONCLUSIONS 
 
We genotyped ten polymorphisms in the MC2R, AR, LRP5, TCF7L2 and FTO genes, and 
determined X-chromosome inactivation patterns in 73 PA children and 97 age- and gender-
matched controls. Based on the differences in genotype distributions and single marker 
association analysis, we can make the following conclusions about the role of genetic variation 
in adrenarche, bearing in mind the limited power of the study. 
 
1) The minor variant of MC2R -2 T>C is more frequent in PP children and is 
associated with higher Δ4-A/cortisol ratio, suggesting a shift in adrenal 
steroidogenesis from corticosteroids to androgens (I). 
2) X-chromosome inactivation plays no major role in the pathogenesis of PA (II). 
3) PA children with a BMI less than the median of the group have a shorter 
mwCAGn in AR, indicating higher androgen sensitivity (III).  
4) PA children with a lower BMI than the median of the group have a higher 
frequency of the diabetes risk-conferring variant of rs7903146 in TCF7L2 (IV).  
5) The obesity-related risk variant of rs9939609 in FTO was found in similar 
frequency in PA and control children, and was not associated with increased 
weight-for-height in PA children (IV). 
6) Genetic variation in LRP5 was not associated with PA, but the minor variants 
were associated with serum DHEAS levels and lipid measures in healthy 
prepubertal children (III). 
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